EIN Presswire: GlaxoSmithKline Live Feed Press Releases

Reportlinker Adds US Vaccines Market

Tue, 07 Sep 2010 14:45:55 +0000

Reportlinker Adds US Vaccines Market

PR Newswire

NEW YORK, Sept. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

US Vaccines Market

http://www.reportlinker.com/p0288102/US-Vaccines-Market.html

US demand to grow 5.5% annually through 2014

Demand for vaccines is forecast to increase 5.5 percent annually to more than $14 billion in 2014. The market has experienced dramatic growth due to increasing routine seasonal influenza immunization and the rising number of preventive and booster vaccines available for adults and adolescents. This growth will be compounded as several new therapeutic vaccines for cancer reach the market, followed in the coming years by biological treatments for Respiratory Syncytial Virus (RSV) and Alzheimer's Disease, and a variety of new vaccines for travel and biodefense.

New routine vaccines to boost adult, adolescent segment

Pediatric vaccines have been the mainstay of the vaccine market for many years, growing steadily as new products emerged and as a greater number of routine vaccinations were encouraged. Now, a substantial number of primary vaccines and boosters are being recommended for adolescents and older adults, and the market for vaccines has expanded dramatically with the addition of these populations to the target markets for vaccine producers. Significant growth in the market has been fueled by the introduction of a vaccine for Human Papillomavirus (HPV), recommended for girls and young women and now being considered for males and a wider age range. Seasonal influenza vaccination is also gaining ground and represents a substantial portion of growth in adult vaccines, as new preventive treatments against zoster and meningococcal disease. Also a factor in adult vaccines is the growing use of boosters against tetanus, diphtheria, pertussis and other diseases.

Combination vaccines to pace pediatric products

Among vaccines for children, sales will be affected by the expiration of patent protection for many of the most widely used vaccines. This has encouraged producers to develop several new combination vaccines, which will serve to maintain the value of products while decreasing the burden of multiple individual injections. Traditional DTaP (diphtheria, tetanus, pertussis) vaccines are being supplemented by products for Hepatitis B and polio or Haemophilus b. Also being developed are vaccines to address a wider range of bacterial serotypes, as with Wyeth's blockbuster PREVNAR7, which has been expanded to address 13 serotypes and which is recommended as a supplement for children who already received the earlier vaccine. Relatively new vaccines, such as that for Rotavirus, continue to mature and to reach greater immunization coverage.

Many new therapeutic vaccines showing promise

Vaccine demand will be spurred considerably by a number of therapeutic vaccines for cancer that are nearing completion of clinical trials and are poised for FDA approval. There are currently 50 cancer vaccines in phase III or later trials, and the activity surrounding cancer vaccine development is expected to continue at a high pace. Also showing promise are vaccines being developed for RSV, HIV and Alzheimer's Disease. Similarly, a range of vaccines for travel, developing countries and biodefense are in the pipeline, including prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague.

Study coverage

This new industry study presents historical demand data (1999, 2004 and 2009) plus forecasts for 2014 and 2019 by major and minor product group. The study also considers market environment factors, details industry structure, evaluates company market share and profiles 17 industry participants.

INTRODUCTION viii

I. EXECUTIVE SUMMARY 1

II. MARKET ENVIRONMENT 4

General 4

Macroeconomic Outlook 5

Demographic Patterns 8

Health Care Trends 11

Health Insurance & Reimbursement 12

Medical Conditions 14

Chronic Conditions 15

Acute Conditions 17

Reportable Diseases 19

National Health Expenditures 22

Medical Facilities & Professionals 24

Patient Activity 27

Animal Health Care 30

Animal Demographic Trends 31

Veterinarians & Other Veterinary Workers 32

Animal Health Expenditures 33

Regulatory Considerations 36

Human Vaccines Regulation 36

Animal Vaccines Regulation 38

III. VACCINE TECHNOLOGIES 39

General 39

Technologies Used in Currently Licensed Products 40

Technologies Under Development 44

Delivery 45

Valence & Combined Vaccines 46

Efficacy 47

IV. PRODUCT OVERVIEW 49

General 49

Major Product Groups 50

Human Vaccines 51

Recommended Childhood Immunizations 54

Recommended Adult & Adolescent Immunizations 55

Animal Vaccines 57

Historical Market Trends 58

International Activity & Foreign Trade 59

Human Vaccines Trade 62

Animal Vaccines Trade 63

V. HUMAN VACCINES 65

General 65

Pediatric Vaccines 67

Combination Vaccines 69

Diphtheria-Tetanus-Pertussis (DTaP) 70

Measles-Mumps-Rubella (MMR) 72

Other Combination Vaccines 75

Pneumococcal (PCV) 76

Varicella 78

Rotavirus 80

Hepatitis 82

Haemophilus b (Hib) 84

Pediatric Seasonal Influenza 86

Polio 88

Adult & Adolescent Vaccines 89

Seasonal Influenza Vaccines 91

Human Papillomavirus 95

Tetanus-Diphtheria-Pertussis (Tdap) 97

Meningococcus 99

Pneumococcus 101

Hepatitis 103

Herpes Zoster 104

Other Adult & Adolescent Vaccines 106

Varicella 107

Tuberculosis 108

Lyme Disease 109

Pandemic Influenza Vaccines 110

Biodefense 113

Anthrax 115

Smallpox 117

Travel Vaccines 119

Developmental Vaccines 125

Cancer 127

Prostate Cancer 129

Lung Cancer 130

Other Cancers 131

Other Developmental Vaccines 132

HIV/AIDS 133

Respiratory Syncytial Virus (RSV) 135

Alzheimer's Disease 137

All Other Developmental Vaccines 138

VI. ANIMAL VACCINES 140

General 140

Livestock Vaccines 142

Bovine Vaccines 143

Porcine Vaccines 146

Ovine Vaccines 148

Companion Animal Vaccines 149

Canine Vaccines 151

Feline Vaccines 152

Equine Vaccines 153

Other Companion Animal Vaccines 155

Poultry Vaccines 155

Other Animal Vaccines 158

VII. INDUSTRY STRUCTURE 160

General 160

Market Share 162

Competitive Strategies 164

Mergers & Acquisitions 166

Licensing & Related Agreements 168

Research & Development 173

Manufacturing 174

Marketing & Distribution 175

Company Profiles 177

AstraZeneca plc 178

Baxter International Incorporated 180

Biogen Idec Incorporated 182

Boehringer Ingelheim GmbH 183

Crucell NV 185

Dow Chemical Company 190

DynPort Vaccine Company LLC 192

Emergent BioSolutions Incorporated 194

GenVec Incorporated 197

GlaxoSmithKline plc 199

Heska Corporation 202

Intervet/Schering-Plough Animal Health, see Merck

MedImmune LLC, see AstraZeneca

Merck & Company Incorporated 204

Merial Limited, see Sanofi-Aventis

Novartis AG 210

Pfizer Incorporated 214

PharmAthene Incorporated 218

Sanofi-Aventis 221

VaxGen Incorporated 227

VaxInnate Corporation 229

Wyeth, see Pfizer

Additional Companies Mentioned in the Study 231

LIST OF TABLES

SECTION I -- EXECUTIVE SUMMARY

Summary Table 3

SECTION II -- MARKET ENVIRONMENT

1 Macroeconomic Indicators 8

2 Population & Households 11

3 Health Insurance Coverage of the US Population 14

4 Chronic Conditions by Type 17

5 Acute Conditions by Type 19

6 Specified Reportable Diseases 21

7 National Health Expenditures 24

8 Selected Medical Facilities & Professionals 27

9 Patient Activity 30

10 Animal Population 32

11 Animal Health Employment 33

12 Animal Health Expenditures 35

SECTION III -- VACCINE TECHNOLOGIES

1 US Licensed Vaccines by Production Technology 42

SECTION IV -- PRODUCT OVERVIEW

1 Vaccines Demand by Major Product Group 51

2 Human Vaccines Licensed for US Sale 52

3 2010 CDC-Recommended Childhood Immunizations 55

4 2010 CDC-Recommended Adolescent Immunizations 56

5 2010 CDC-Recommended Adult Immunizations 56

6 Vaccines Market, 1999-2009 59

7 US Trade in Vaccines 62

8 US Trade in Human Vaccines 63

9 US Trade in Animal Vaccines 64

SECTION V -- HUMAN VACCINES

1 Human Vaccines Demand 67

2 Pediatric Vaccines Demand by Type 69

3 Pediatric Combination Vaccines Demand 70

4 Diphtheria, Tetanus & Pertussis (DTaP)

Combination Vaccines Demand 72

5 Measles, Mumps & Rubella (MMR)

Combination Vaccines Demand 75

6 Other Combination Vaccines Demand 76

7 Pediatric Pneumococcal Vaccines Demand 78

8 Varicella Vaccines Demand 80

9 Rotavirus Vaccines Demand 82

10 Pediatric Hepatitis A & B Vaccines Demand 84

11 Haemophilus b (Hib) Vaccines Demand 86

12 Pediatric Seasonal Influenza Vaccines Demand 88

13 Polio Vaccines Demand 89

14 Adult & Adolescent Vaccines Demand by Group & Condition 91

15 Adult & Adolescent Seasonal Influenza Vaccines Demand 95

16 Human Papillomavirus (HPV) Vaccines Demand 97

17 Tetanus-Diphtheria-Pertussis (Tdap) Vaccines Demand 99

18 Meningococcal Vaccines Demand 101

19 Adult & Adolescent Pneumococcal Vaccines Demand 103

20 Adult & Adolescent Hepatitis A & B Vaccines Demand 104

21 Herpes Zoster Vaccines Demand 106

22 Other Adult & Adolescent Vaccines Demand 107

23 Pandemic Influenza Vaccines Demand 113

24 Biodefense Vaccines Demand 115

25 Travel Vaccines Demand 120

26 Developmental Vaccines Demand 127

27 Cancer Vaccines Demand 129

28 Other Developmental Vaccines Demand 133

SECTION VI -- ANIMAL VACCINES

1 Animal Vaccines Demand 141

2 Livestock Vaccines 143

3 Companion Animal Vaccines Demand 150

4 Poultry Vaccines Demand 158

5 Other Animal Vaccines Demand 159

SECTION VII -- INDUSTRY STRUCTURE

1 US Vaccines Revenues by Company, 2009 161

2 Selected Acquisitions & Divestitures 167

3 Selected Cooperative Agreements 171

LIST OF CHARTS

SECTION VII -- INDUSTRY STRUCTURE

1 US Human Vaccines Market Share by Company, 2009 162

2 US Animal Vaccines Market Share by Company, 2009 163

To order this report:

Biotechnology Industry: US Vaccines Market

Biotechnology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Bedford Laboratories™ to Begin Shipping Sumaptriptan Succinate Injection, 6mg (base)/0.5 mL Packaged in Pre-Filled Syringes

Tue, 07 Sep 2010 12:00:00 +0000

Bedford Laboratories™ to Begin Shipping Sumaptriptan Succinate Injection, 6mg (base)/0.5 mL Packaged in Pre-Filled Syringes

PR Newswire

BEDFORD, Ohio, Sept. 7 /PRNewswire/ --– Bedford Laboratories™ is excited to announce they have further diversified their product offerings with the addition of pre-filled syringes. FDA approval has been granted and Sumaptriptan Succinate Injection, 6mg (base)/0.5 mL pre-filled syringes are now available. This is a very important product addition to their expanding portfolio of products. Sumaptriptan Succinate Injection is indicated for the acute treatment of migraine attacks with or without aura, and the acute treatment of cluster headache episodes. The product is AP rated to Imitrex®

(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.

Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. and a member of the Boehringer Ingelheim group of companies. For more information on Bedford Laboratories, visit www.bedfordlabs.com.

Imitrex® is a registered trademark of GlaxoSmithKline

SOURCE Bedford Laboratories

Idenix Provides Update on HCV Clinical Development Activities

Tue, 07 Sep 2010 11:00:00 +0000

Idenix Provides Update on HCV Clinical Development Activities

- Conference call today at 8:30 am ET

PR Newswire

CAMBRIDGE, Mass., Sept. 7 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. This decision was made after Idenix notified the FDA of three serious adverse events that occurred during a drug-drug interaction study of the combination of IDX184 and IDX320 in healthy volunteers. These observed serious adverse events were elevated liver function tests detected in three subjects during post exposure safety visits. The liver function tests have returned to nearly normal levels in all three subjects during follow-up. All planned studies of IDX184 and IDX320 to date have been completed and there are currently no healthy volunteers or patients receiving IDX184 or IDX320. Idenix will submit full data to the FDA from recently completed preclinical and clinical studies, including 3-month chronic toxicology studies of IDX184, a 14-day study of IDX184 in combination with pegylated interferon/ribavirin (PegIFN/RBV), a 3-day proof-of-concept study of IDX320 in hepatitis C (HCV) infected patients, and the IDX184 and IDX320 drug-drug interaction study in healthy volunteers in order to assess next steps in the development of both compounds.

"We have not yet received a formal letter from the FDA, nor has the Agency had an opportunity to review the safety and efficacy data from recently completed clinical trials with IDX184 and IDX320. Based upon our discussions with the Agency, we are primarily focused on three cases of elevated liver function tests observed during our drug-drug interaction study of the combination of IDX184 and IDX320 in healthy volunteers," said Jean-Pierre Sommadossi, Ph.D., Idenix Chairman and Chief Executive Officer. "Based upon the safety and antiviral activity we observed in the IDX184 14-day study and the IDX320 3-day proof-of-concept study, both in HCV-infected patients, we remain committed to the future potential of these drug candidates. We will work closely with independent experts and our external safety committee to better understand the cause of these serious adverse events in the combination study of IDX184 and IDX320 and to provide the FDA with more information in order to expedite their review and resolve this matter as quickly as possible."

Full data presentations of IDX184, IDX320 and IDX375 studies will be presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which will be held at the end of October in Boston.

Phase I: IDX184/IDX320 Combination

Idenix completed a two-week Phase I, randomized, double-blind, placebo-controlled study to evaluate the safety and pharmacokinetic drug-drug interaction between IDX320 and IDX184 in healthy volunteers. Two cohorts were evaluated in the study with 10 subjects in each cohort randomized eight to active drug and two to placebo. Subjects in the first cohort received 400 mg once-daily of IDX320 for the first week, subsequently adding 100 mg once-daily of IDX184 for the second week. Subjects in the second cohort received 100 mg once-daily of IDX184 plus placebo for the first week, subsequently adding 400 mg once-daily of IDX320 for the second week. The combination of IDX184 and IDX320 was generally safe and well tolerated during the 14 days of treatment. Liver function abnormalities deemed to be serious adverse events were detected in three subjects during the post exposure safety visits. Liver function tests in these subjects have returned to nearly normal during follow-up. Pharmacokinetic drug-drug interactions between IDX184 and IDX320 were not considered to be clinically significant. Neither the plasma exposure of IDX184 and its metabolite, 2'-methylguanosine, nor IDX320 plasma exposure explain these three serious adverse events.

Phase IIa: IDX184, a liver-targeted HCV nucleotide prodrug

This 14-day, Phase IIa clinical trial evaluated 50 to 200 mg doses of IDX184 in combination with PegIFN/RBV in treatment-naive HCV genotype 1-infected patients. At Day 14, mean (+/- standard deviation) viral load reductions were 1.5 (+/- 1.3) logs for placebo (n=16), 2.7 (+/- 1.3) logs for 50 mg IDX184 QD (n=16), 4.0 (+/- 1.7) logs for 50 mg IDX184 BID (n=8), 4.2 (+/- 1.9) logs for 100 mg QD (n=8), 4.1 (+/- 1.2), for 150 mg QD (n=15), 4.1 (+/-1.4) logs for 100 mg BID (n=8) and 3.7 (+/- 1.2) logs for 200 mg QD (n=8). In the cohorts of 100 mg, 150 mg, and 200 mg daily doses in combination with PegIFN/RBV, 50%, 40% and 25%, respectively, of patients achieved undetectable virus levels (<15 IU/mL) by Day 14. Liver injury parameters (ALT and AST) improved with all doses of IDX184. The side effect profile of the three drug combination was consistent with the known side effect profile of PegIFN/RBV alone. The most common adverse events reported were fatigue, myalgia, headache and nausea.

Phase I/II: IDX 320, an HCV protease inhibitor

This randomized, parallel-arm, double-blind, placebo-controlled proof-of-concept trial evaluated the safety, tolerability, antiviral activity and pharmacokinetics of IDX320 in treatment-naive HCV genotype 1-infected patients. Thirty patients were randomized equally and received placebo, 50, 100, 200 or 400 mg of IDX320 orally once-a-day for three days. One cohort of eight patients was randomized to receive 200 mg IDX320 BID or placebo. At Day 3, mean (+/- standard deviation) viral load reductions were 0.1 (+/- 0.15) logs for placebo (n=5), 2.6 (+/-0.49) logs for 50 mg IDX320 QD (n=5), 3.1 (+/- 0.29) logs for 100 mg QD (n=6), 3.1 (+/- 0.41) logs for 200 mg QD (n=6) and 3.3 (+/- 0.28) logs for 400 mg QD (n=7). At daily doses of placebo, 50, 100, 200, and 400 mg, 0%, 20%, 67%, 67% and 86%, respectively, of patients achieved greater than or equal to 3 log reduction in HCV RNA at the end of treatment. In the 200 mg IDX 320 BID cohort at Day 3, mean (+/- standard deviation) viral load reductions were 3.8 (+/- 0.52) logs and all patients (100%) achieved greater than or equal to 3 log reduction in HCV RNA. In the 3-day proof-of-concept study, IDX320 was generally safe, well tolerated, and demonstrated potent, dose-related HCV antiviral activity.

Phase I: IDX375, an HCV non-nucleoside polymerase inhibitor

Idenix has an ongoing Phase I clinical trial in healthy volunteers evaluating single doses of the free acid form of IDX375 ranging from 200 to 1200 mg per day. Overall, IDX375 achieved pharmacologically relevant drug exposure and was well tolerated for doses up to 1200 mg for one day in healthy subjects. In the fourth quarter of 2010, Idenix plans to initiate a 3-day proof-of-concept trial in treatment-naive genotype 1 HCV-infected patients.

Conference Call Information

Idenix will hold a conference call today at 8:30 a.m. ET. To access the call please dial (800) 471-3635 U.S./Canada or (706) 758-9475 International and enter passcode 99538089. A replay of the conference call and webcast will be available until September 21, 2010. To access the replay, please dial (800) 642-1687 U.S./Canada or (706) 645-9291 International and enter the passcode 99538089.

About HCV

Hepatitis C virus is a common blood-borne pathogen infecting three to four million people worldwide annually. Currently, an estimated 170 million people are infected worldwide, representing a nearly 5-fold greater prevalence than human immunodeficiency virus.(1)

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.

Forward-Looking Statements

This press release contains "forward-looking statements" for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including but not limited to the statements regarding the company's future business and financial performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "expect," "plans," "anticipates," "will," "expects," "goal," "estimates," "projects," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements, as are expressed or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of our drug candidates, the likelihood and success of any future clinical trials involving our drug candidates or successful development of novel combinations of direct-acting antivirals for the treatment of hepatitis C. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; management's expectations could be affected by unexpected regulatory actions or delays, including the current clinical hold on IDX184 and IDX320; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaborations with Novartis Pharma AG and GlaxoSmithKline; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in each of the company's annual report on Form 10-K for the year ended December 31, 2009 and quarterly report on form 10-Q for the quarter ended June 30, 2010, as filed with the Securities and Exchange Commission (SEC) and in any subsequent periodic or current report that the company files with the SEC.

All forward-looking statements reflect the company's estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the company's estimates change.

(1) Lavanchy (2009) Liver International. 29(s1):74-81

Idenix Pharmaceuticals Contact:
Jonae Barnes (617) 224-4485 (investors)
Kelly Barry (617) 995-9033 (media)

SOURCE Idenix Pharmaceuticals, Inc.

AMM Announces The Doctors' Choice Awards Finalists: Over 4,600 MDs Vote for Best Journal Ads in AMM's Doctors' Choice Awards

Wed, 01 Sep 2010 17:10:26 +0000

AMM Announces The Doctors' Choice Awards Finalists: Over 4,600 MDs Vote for Best Journal Ads in AMM's Doctors' Choice Awards

PR Newswire

MOUNT LAUREL, N.J., Sept. 1 /PRNewswire-USNewswire/ -- The Association of Medical Media (AMM) has announced The Doctors' Choice Awards ad finalists from 21 specialties based on research on advertisements appearing in 2009. The creative teams that worked on the winning advertisements will be recognized at The Doctors' Choice Awards on Thursday, September 16, 2010 from 3:30 – 6:30 p.m. at Comix Comedy Club, located at 353 West 14th Street in New York City.

The research on MD preferences was conducted by computer solicitation on 325 advertisements representing the 86 most widely-advertised products in 2009. The study was conducted by Readex Research, and drew more than 4,600 responses. This is the seventh year AMM has conducted The Doctors' Choice research.

"Given the significance of pharmaceutical developments for patients and professionals alike, we're pleased to continue spearheading The Doctors' Choice Awards," said AMM President Tino DeCarlo. "This program shines a light on truly innovative, effective advertisements, and recognizes the teams that so seamlessly work together to produce pieces intended to catch the eye of general practitioners and specialists across the healthcare spectrum."

The advertisements were judged on their ability to communicate clearly and quickly, help with clinical decisions, prompt seeking more information or re-examining treatment, generate interest, add to information provided by company sales representatives and underscore the value of the product prescribed.

The finalists' advertisements, their manufacturers and the agencies responsible for them are:

CATEGORY	PRODUCT	COMPANY	AGENCY	PAGES
Anesthesiology
	Opana	Endo Pharmaceuticals	Stonefly Communications Group	3
	OxyContin Tablets	Purdue Pharma	LyonHeart	1
	Precedex	Hospira	Goble & Associates	1
Cardiology
	Bystolic	Forest	Sudler & Hennessey	3
	Plavix	Bristol-Myers Squibb/Sanofi Aventis	Torre Lazur McCann	2
	Simcor Tablets	Abbott	Sudler & Hennessey	2
Dermatology
	Epiduo Gel	Galderma	Echo Torre Lazur	1
	ORACEA	Collagenex	Sudler & Hennessey	1
	Vectical	Galderma	Sudler & Hennessey	2
Endocrinology
	Byetta	Amylin Pharmaceuticals	Palio Communications	1
	Levemir	Novo Nordisk	CDM	1
	Welchol	Daiichi Sankyo	Area 23	3
Emergency Medicine
	Plavix	Bristol-Myers Squibb/Sanofi Aventis	Torre Lazur McCann	2
	Tygacil	Wyeth	Ogilvy	2
	Zyvox	Pfizer	CDM	1
General Surgery
	Entereg	Adolor/GlaxoSmithKline	Torre Lazur McCann	2
	Tygacil	Wyeth	Ogilvy	2
	Zyvox	Pfizer	CDM	1
Infectious Disease
	Prezista	Tibotec	ICC	3
	Reyataz	Bristol-Myers Squibb	DraftFCB	3
	Truvada	Gilead	Abelson Taylor	1
Oncology
	AVASTIN	Genentech	Harrison and Star	1
	Herceptin	Genentech BIOONCOLOGY	Flashpoint Medica	1
	Rituxan	Genentech Biogen Idec	Abelson Taylor	1
Ophthalmology
	Combigan	Allergan	Pacific Communications	2
	Lumigan	Allergan	Pacific Communications	1
	XALATAN	Pfizer	Euro RSCG Life LM&P	2
Orthopedic Surgery
	CELESTONE SOLUSPAN	Schering-Plough	Merck	1
	Euflexxa	Ferring Pharmaceuticals	Sudler & Hennessey	1
	Synvisc One	Genzyme	Wishbone	1
Pediatric
	Lexapro	Forest	Grey Healthcare	4
	ProAir	Teva Pharmaceuticals	GSW Worldwide/Intouch Solutions	1
	Rotarix Vaccine	GlaxoSmithKline	DraftFCB	2
Gastroenterology
	HalfLytely	Braintree	LyonHeart	2
	Lialda	Shire US	Euro RSCG	2
	VIREAD	Gilead	Medicus Life Brands	4
Nephrology
	Ferrlecit	Sanofi-Aventis	Saatchi & Saatchi/Healthcare Innovations	1
	Myfortic Tablet	Novartis	Revolution Health	2
	Venofer	American Regent	5 Strong Healthcare	2
Neurology
	AVONEX	Biogen Idec	Euro RSCG Life Metamax	2
	COPAXONE	Teva Neuroscience	Harrison and Star	2
	Tysabri	Biogen Idec	Euro RSCG	4
Physician Assistant / Nurse Practitioners
	Aldara	Graceway	Metaphor	1
	Naprelan	Victory Pharma	Victory Pharma	1
	Yaz	Bayer Healthcare	CommonHealth	2
Rheumatology
	Enbrel	Amgen/Pfizer	Saatchi & Saatchi	2
	Rituxan	Genentech Biogen Idec	AgencyRx	2
	Savella	Forest	Ferguson	3
Urology
	Gelnique	Watson	Core-Create	3
	RAPAFLO	Watson	Wedgewood Communications	4
	Trelstar LA	Watson	Wedgewood Communications	2
Psychiatric
	Geodon	Pfizer	LyonHeart	1
	INVEGA	Janssen	Grey Healthcare	2
	Lexapro	Forest	Grey Healthcare	2
Multi-Specialty
	Kapidex Capsules	TAP Pharmaceuticals	Abelson Taylor	3
	Levemir FlexPen	Novo Nordisk	CDM	1
	Lexapro	Forest	Grey Healthcare	4
Pulmonology
	Tracleer	Actelion	Giant	1
	Ventavis	Actelion	Giant	1
	Zyvox	Pfizer	CDM	1


Obstetricals/ Gynecologicals
	Aldara	Graceway Pharmaceuticals	Metaphor	1
	EVISTA	Lilly	Abelson Taylor	2
	Premarin Vaginal Cream	Wyeth	Harte Hanks	1

At the reception, awards will also be presented to the highest-scoring advertisement.


Highest Scoring Ad Overall Finalists
	AVASTIN	Genentech	Harrison and Star	5
	Lexapro	Forest	Grey Healthcare	2
	Rituxan	Genentech Biogen Idec	Abelson Taylor	1

Tickets for the awards reception are $180 for AMM members and $215 for non-members. Discounts are also available for reservations made for groups of five or ten attendees. Contact AMM at 856-380-6814 for information regarding the event and ticket purchases, or visit the association's Web site at www.ammonline.org.

About the Association of Medical Media

Celebrating its 35th year, the Association of Medical Media (AMM) is dedicated to educating and promoting the value of the medical publishing and communications industry. AMM's name reflects its membership: medical publishing firms, content providers and associated companies in the medical communications field. Through regular networking opportunities and our unique industry partnerships, AMM aims to be the leader in the future development of medical media. For more information, visit www.ammonline.org.

SOURCE Association of Medical Media

Dazzling Array of Stars to Light Up Stand Up To Cancer September 10th Broadcast

Wed, 01 Sep 2010 13:00:00 +0000

Dazzling Array of Stars to Light Up Stand Up To Cancer September 10th Broadcast

PR Newswire

George Clooney, Gwyneth Paltrow, Will Smith, Denzel Washington, Renee Zellweger and More Join Landmark One-Hour Event Simultaneously Broadcast on ABC, CBS, FOX, NBC and a Host of Cable Channels

A Special Half-Hour Pre-Show Promotion Hosted by Cat Deeley Will Air Online; Celebrity Phone Banks Open as of 7:30 PM EDT / 4:30 PM PDT

A Half-Hour Extended-Play LIVE Online "Jam Session" Rounds Out the Evening

LOS ANGELES and NEW YORK, Sept. 1 /PRNewswire-USNewswire/ -- (www.standup2cancer.org) – The extraordinary lineup of actors, musicians, athletes and journalists participating in the Stand Up To Cancer (SU2C) primetime roadblock television fundraising event (September 10, 2010, at 8PM EDT & PDT / 7PM CT) continues to grow. The following supporters have now joined the broadcast: Elizabeth Banks, Kathy Bates, Sir Richard Branson, Michael Chiklis, George Clooney, Baron Davis, Emily Deschanel, Bill Hader, Dorothy Hamill, Anne Heche, Cheryl Hines, Randy Jackson, George Karl, Dr. Jon Lapook, Rob Lowe, Jane Lynch, Marlee Matlin, Shareen Mitchell, Olivia Munn, Lisa Niemi, Kelly Osbourne, Gwyneth Paltrow, Matt Passmore, Will Smith, Sam Trammell, Denzel Washington, Aaron Yoo and Renee Zellweger.

Musical guests scheduled to perform include: Billie Joe Armstrong of Green Day, Neil Diamond, The Edge, Delta Goodrem, Herbie Hancock, Kris Kristofferson, Lady Antebellum, Leona Lewis, Orianthi and Ann Wilson and Nancy Wilson of Heart. These artists join previously announced performers including Natasha Bedingfield, Martina McBride, Aaron Neville, Dave Stewart and Stevie Wonder.

The Stand Up To Cancer (SU2C) telecast will raise funds that will accelerate innovative cancer research. The live, one-hour fundraising event will be simulcast commercial-free on ABC, CBS, FOX, NBC, Bio, Current TV, Discovery Health, E!, G4, HBO, HBO Latino, MLB Network, mun2, Showtime, Smithsonian Channel, The Style Network, TV One and VH1 and hosted by network news anchors Katie Couric, Diane Sawyer and Brian Williams. The broadcast will air in 195 countries, as well as on the Armed Forces Network.

"Plain and simple, cancer takes too much from us," said Laura Ziskin, SU2C co-founder and executive producer of the September 10th broadcast, who is a cancer survivor. "Loved ones lost to it, pain and suffering endured by those in treatment, even the recent report that cancer has the most devastating economic impact of any cause of death…this disease exacts a very high price. We want people all over the country to rise up and say, 'ENOUGH!'

"Tune in on Sept. 10th to see your favorite stars, who'll ask, 'Will you stand up with us?' Person by person, saying 'yes' moves us toward a goal completely within our grasp: a world without cancer. A donation of any size brings scientists one step closer to a cure," Ziskin said.

Cat Deeley of FOX's So You Think You Can Dance will host the pre-show promotion to kick off the evening as the celebrity phone bank opens at 7:30 PM EDT / 4:30 PM PDT. A 30-minute online "after hours" extended play featuring jams with musical guests Fitz and the Tantrums, Orianthi, Natasha Bedingfield and Heart will conclude the night's events. The pre-show promotion and extended play will be featured on numerous online portals and destination sites (which will all also stream the one-hour special online) including: ABC, ABC News, AOL, Bing, CBS, CBS News, Crackle, Discovery Health, E! Online, FOX, G4, Hulu, Livestream, MLB Network, MSN, mun2, NBC, Style Network, TV Guide, TV One, Ustream, VEVO, VH1, Wonderwall.MSN.com, omg.yahoo.com and YouTube.

Previously announced participants in the September 10th special include: Kareem Abdul-Jabbar, Tatyana Ali, Dave Annable, Christina Applegate, Lance Armstrong, David Boreanaz, Abigail Breslin, Cindy Crawford, Fran Drescher, Elizabeth Edwards, Donald Faison, Sally Field, Derek Fisher, Michael C. Hall, Alyson Hannigan, Tony Hawk, Jon Heder, Marg Helgenberger, Terrence Howard, Ken Jeong, Rashida Jones, Minka Kelly, Laura Linney, Zachary Levi, Ray Liotta, Seth MacFarlane, Mandy Moore, Apolo Anton Ohno, Dr. Mehmet Oz, Jim Parsons, Aubrey Plaza, Dr. Ana Maria Polo, Yarel Ramos, Naya Rivera, Robin Roberts, Seth Rogen, The Simpsons, Eric Stonestreet, Marcia Strassman, Alison Sweeney, Maura Tierney, Gabrielle Union, Sofia Vassilieva, Sofia Vergara, Marissa Jaret Winokur, Reese Witherspoon and Ethan Zohn.

Also appearing on the September 10th special as an inspiration to those currently in the fight against cancer are Anne Feeley and Pearce Quesenberry. A brain cancer survivor, Anne Feeley, at age 55, recently cycled from San Francisco to Washington, D.C., to generate awareness about and funds for the fight against the disease. Pearce Quesenberry is a 13-year-old who was featured in the 2008 Stand Up To Cancer broadcast as she was battling brain cancer. Pearce is now cancer-free, and will participate in this year's broadcast as a survivor.

The broadcast is dedicated to the 12 million U.S. cancer survivors, illustrating how groundbreaking research can change the tide in the fight against the disease. Updates will be provided on the work of the five Stand Up To Cancer Dream Teams, and Dr. Sanjay Gupta, CNN's Chief Medical Correspondent, will report on other new medical developments.

SU2C's star-studded television special builds continuing public support and donations for cutting-edge cancer research that translates at a rapid pace from the laboratory to treatments and technologies benefiting patients. One-hundred percent of all donations received from the public will go directly to cancer research. Viewers will have the ability to donate via a dedicated phone line, the web, or through text.

The 2008 telecast helped raise over $100 million. To date, five multi-disciplinary "Dream Teams" of researchers from more than 50 institutions, as well as 13 young innovative scientists who are undertaking high-risk yet potentially high-reward projects have received SU2C funding. SU2C brings together these scientists from different disciplines across various institutions to work collaboratively, rather than competitively, at a critical time in the field of cancer research.

The American Association for Cancer Research (AACR), which consists of more than 32,000 scientists engaged in the fight against cancer, is Stand Up To Cancer's sole scientific partner. The AACR, the oldest and largest scientific organization in the world focusing on every aspect of high-quality, innovative cancer research from the bench to the bedside, is responsible for administering and managing the grants, and providing scientific oversight in conjunction with the SU2C Scientific Advisory Committee, led by Nobel Laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.

About the Stand Up To Cancer Initiative

Stand Up To Cancer (SU2C) – a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization – raises funds to hasten the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. In the fall of 2007, a group of women who have been profoundly affected by cancer began working together to marshal the resources of the media and entertainment industries in the fight against it.

Stand Up To Cancer will return to primetime TV on September 10, 2010, at 8PM EDT & PDT / 7PM CT. The one-hour fundraising event will be simulcast live and commercial-free on ABC, CBS, FOX, NBC, Bio, Current TV, Discovery Health, E!, G4, HBO, HBO Latino, MLB Network, mun2, Showtime, Smithsonian Channel, The Style Network, TV One and VH1.

The SU2C founding members include Laura Ziskin, executive producer of the Sept. 5, 2008 broadcast and the upcoming one, who is a cancer survivor; Sherry Lansing, chairperson of the Entertainment Industry Foundation's Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; Katie Couric; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; nonprofit executive Ellen Ziffren; and Noreen Fraser, founder of the Noreen Fraser Foundation (NFF) and a cancer survivor. SU2C was formally launched on May 27, 2008.

Major League Baseball was the founding donor to contribute to Stand Up To Cancer. Other major SU2C supporters include Sidney Kimmel, the country's largest individual supporter of cancer research; Amgen, Bloomberg Philanthropies, Cancer Treatment Centers of America, The Gateway for Cancer Research Foundation, GlaxoSmithKline, Inter-American Development Bank (IDB), Wallis Annenberg & The Annenberg Foundation, Alliance for Global Good, Milken Family Foundation, Philips Electronics, Steve Tisch, The Island Def Jam Music Group, Comcast and many others. SU2C major media partners include AOL, Bonnier Corporation, Conde Nast Media Group, Costco Connections, eBay Inc., Facebook, Hearst Corporation, iTunes, MySpace, Rodale, Inc., Los Angeles Times, Martha Stewart Living, Meredith Corporation, Time Inc., Twitter, VEVO and YouTube.

About the Entertainment Industry Foundation

Stand Up To Cancer is a program of the Entertainment Industry Foundation (EIF), the 501(c)(3) not-for-profit organization that serves as the collective philanthropy for the television and film businesses. EIF has distributed hundreds of millions of dollars to support programs addressing critical health, education and social issues.

SOURCE Entertainment Industry Foundation

Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015

Tue, 31 Aug 2010 17:09:04 +0000

Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015

PR Newswire

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015

http://www.reportlinker.com/p0285781/The-Outlook-for-Pharmaceuticals-In-The-Middle-East-And-North-Africa-To-2015.html

Attractive macro-environmental conditions

Political, economic, social and demographic development is making the pharmaceutical markets in the Middle East & North Africa (MENA) region more attractive. The Economist Intelligence Unit (EIU) forecasts that the five MENA markets covered in this collection will represent a combined GDP of US$2.3 trillion in 2015, led by Turkey and Saudi Arabia. Economic development is changing the epidemiological health profile in the region, with the increasing prevalence of communicable diseases. In demographic terms, the population in these five MENA markets is still young and is expected to reach 240.4 million in 2015, headed by Egypt and Turkey. Nevertheless, there is a sizeable elderly population which will demand more healthcare services.

Healthcare development towards privatisation

The population has different levels of expectations in each national healthcare system. The healthcare system in Egypt, for instance, is in a transitory phase, characterised by progress towards privatisation. While access to free healthcare exists, private services are appearing as a result of the decline in the standard of public sector care. There is a need for considerable investment in order to continue the modernisation of programmes and maintain the existing facilities. There are two main areas of reform: primary healthcare and the provision of a national health insurance scheme. In Morocco, the health insurance system is in a transitional phase. Overall, opportunities exist, particularly in Turkey and Egypt, as combined health expenditure in these five markets is projected at US$120.3 billion in 2015.

Increasing pharmaceutical demand

International companies recognise the value and potential of these five MENA pharmaceutical markets. sanofi-aventis, for instance, is the largest pharmaceutical operation in Morocco, whilst GlaxoSmithKline is the leader in Saudi Arabia. Some local producers, such as Hikma from Jordan and SPIMACO from Saudi Arabia, aim to become regional leaders. The projected CAGR for the region is very attractive compared to mature markets or other emerging markets. In fact, the MENA pharmaceutical market is expected to represent a combined valued of US$35.9 billion at retail prices in 2015, including pharmacy and hospital sales. The region is headed by Turkey, followed by Egypt and Saudi Arabia. Local manufacturing production is fragmented and geared towards branded generics, but reliance on imports remains. Biotechnology is still in its infancy.

Highlights from the region

Egypt

Positive economic and demographic factors are expected to drive pharmaceutical market growth. However, healthcare provision is highly fragmented. Regulatory advancements in the internal market will increase manufacturing opportunities, although concerns remain regarding drug price referencing, introduced in 2009. The private pharmacy sector has increased by a high double digit CAGR in recent years, but per capita consumption is still low. The pharmaceutical market is expected to grow by a high CAGR over the next few years, as domestic production is expected to rise and as the healthcare system continues in its transition towards modernisation. There are a number of leading local private producers, some of them involved in biotechnology, which are strengthening their manufacturing capabilities.

Jordan

Although it lacks the oil reserves of many of its neighbours and is relatively poor in comparison, Jordan boasts good links with the West and is a key player on the local political scene. Jordan' s stable economy and rapid population growth are both instrumental in the steady growth of the pharmaceutical market. However, the small population naturally limits market size. The country has a relatively strong level of domestic pharmaceutical production; however, the majority is exported, resulting in a market still dependent on imports. Jordan adheres to WTO rules, in particular the TRIPS agreement. This is exemplified by the recent improvements to, and enforcement of, intellectual property protection.

Morocco

Increasing GDP per capita and health expenditure is expected to encourage drug consumption. The pharmaceutical sector has entered a new phase of development with the adoption of new pharmaceutical legislation, which provides a modern legal framework for the pharmaceutical sector. Although the pharmaceutical market is small in global terms, per capita pharmaceutical spending is comparatively high for an African country. The government aims to cut drug prices and encourage generics consumption in 2010, following a Parliamentary report published in November 2009. There is a well-developed manufacturing industry, but competition from France is increasing; sanofi-aventis is by far the largest pharmaceutical operation, both in terms of production and total sales.

Saudi Arabia

The Saudi pharmaceutical market is the richest in the Gulf region. The private pharmacy sector tends to favour branded pharmaceuticals but is marked by tight price controls. The leading operational companies are GlaxoSmithKline and SPIMACO; the latter is rumoured to be interested in the acquisition of an Egyptian pharmaceutical producer in 2010. The public sector, more genericled, is dependent on oil revenues and is characterised by cost-containment and late payments for tenders. There is little domestic production, therefore the vast majority of the market is provided by imports. However, Saudi Arabia imports a large amount of semi-finished medicaments, some of which are then re-labelled, repackaged and exported. In terms of research, the Ministry of Commerce & Industry has identified biotechnology as an area of investment in the country.

Turkey

Turkey is the largest MENA pharmaceutical market, due to its sizeable population and large GDP. The legal environment, however, will pose challenges in the forecast period. Turkey' s negotiations on EU accession continue but the country is not expected to become a member state until at least 2015. In this context, Turkey has sought to align its national pharmaceutical legislation with that of the EU, but the harmonisation process is still incomplete. The market is expected to grow by a moderately high CAGR in US dollar terms between 2010 and 2015; however, the government' s ongoing healthcare reforms may slightly temper the rate of growth, particularly with regards to price controls. Overall, the market will continue to be driven by import growth and generics consumption

Egypt: World Pharmaceutical Market Q2 2010

EXECUTIVE SUMMARY

Snapshot: Strategic Espicom Analysis

Snapshot: Key Data Projections

MACROENVIRONMENT

POLITICAL

ECONOMIC Projections

LEGAL Intellectual Property Rights

DEMOGRAPHIC Projections

Demographic Indicators

EPIDEMIOLOGY

DISEASE BURDEN

DISEASE PREVALENCE Communicable Diseases

Non-Communicable Diseases Cancer

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS

ORGANISATION Government Sector (Ministry of Health)

Public Sector

Private Sector

Healthcare Reforms Healthcare Sector Reform Project

EXPENDITURE Projections

Health Insurance Health Insurance Bill

Health Insurance Systems Development Project

Health Insurance Beneficiaries

INFRASTRUCTURE

SERVICES Hospital Inpatient Services

WORKFORCE Projections

REGULATORY AFFAIRS

PHARMACEUTICAL REGISTRATION

NATIONAL DRUGS POLICY Essential Drugs List

PRICING & REIMBURSEMENT

PRICING New Drug Pricing Decree

DISTRIBUTION CHANNELS

WHOLESALING Public Wholesalers El-Gomhouria

El-Masriya

Private Wholesalers Multipharma

RETAILING Pharmacy Chains El-Ezaby Pharmacy Chain

Misr Pharmacies

Seif Pharmacies

MARKET ANALYSIS

SIZE Projections

Current Size

Current Structure

PRODUCT DEVELOPMENT

MANUFACTURING

TRADE Exports

Imports

Balance of Trade

COMPETITION

TRADE ASSOCIATIONS AUPAM

FEI

TRADE FAIR

COMPANY INTELLIGENCE Public Sector Producers ADCO

Alexandria

CID

El-Nasr

Kahira

Memphis

Misr

Nile

Local Private Producers ACDIMA

EIPICO

Minapharm

MultiApex

October Pharma

Pharco Corporation

SEDICO

Foreign Private Producers AstraZeneca

GlaxoSmithKline

Hikma

Novartis

sanofi-aventis

Competitive Strategies

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

PRICING New Drug Pricing Decree

MARKET

BIOLOGICS & BIOSIMILARS

REGULATION

DISTRIBUTION

PRODUCT DEVELOPMENT

COMPETITION Company Intelligence Arab Company for Medical Appliances

EIPICO

Nile

Rhein Minapharm Biogenetics

CONCLUSIONS: OPPORTUNITIES & CHALLENGES

Strategic Espicom Analysis MACROENVIRONMENT

EPIDEMIOLOGY

HEALTHCARE

REGULATORY AFFAIRS

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET

COMPETITION

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

Radar Analysis

SWOT Analysis

DIRECTORY

GOVERNMENT ORGANISATIONS

PRODUCERS Local Public Holding

Local Private Producers

Foreign Private Producers

TRADE ASSOCIATIONS

LIST OF TABLES

Espicom Analysis of the Pharmaceutical Market, 2010 Summary of Key Data Projections, 2010-2015 Political Landscape, 2010 Regional Comparison of Projected Economies, 2015 Projected Economy, 2010-2015 Regional Comparison of Projected Demographics, 2015 Projected Demographics, 2010-2015 Population by Governorate, 2002/2006 Demographic Indicators, 2000-2007 Regional Comparison of Projected Health Expenditure, 2015 Health Expenditure, 2010-2015 Beneficiaries from Health Insurance System, 1999-2008 Hospital Beds, 2000-2009 Public & Village Hospitals and Rural Health Units, 2000-2008 Regional Comparison of Projected Physicians, 2015 Projected Physicians, 2010-2015 Medical Personnel, 2000-2008 Regional Comparison of Projected Pharmaceutical Markets, 2015 Projected Pharmaceutical Market, 2010-2015 Pharmaceutical Market, 2010 Pharmacy Sector by Origin, 2004/2008 (LE Million) Pharmacy Sector by Origin, 2004/2008 (Million Units) Pharmaceutical Producers, 2006 Pharmaceutical Exports by Category, 2004-2008 (US$000s) Pharmaceutical Exports by Country/Region, 2008 (US$000s) Pharmaceutical Imports by Category, 2004-2008 (US$000s) Imports of Raw Materials by Country/Region, 2008 (US$000s) Imports of Antisera & Vaccines by Country/Region, 2008 (US$000s) Imports of Medicaments by Country/Region, 2008 (US$000s) Pharmaceutical Balance of Trade, 2004-2008 (US$000s) HOLDIPHARMA' s Affiliated Companies, 2010 HOLDIPHARMA' s Joint-Ventures, 2010 HOLDIPHARMA Affiliates' Combined Financial Indicators, FY 2006/2007-FY2008/2009 Pharco Corporation' s Indicators by Subsidiary, 2009 Espicom Analysis of the Pharmaceutical Market, 2010 SWOT Analysis of the Pharmaceutical Market, 2010

LIST OF CHARTS

Regional Comparison of Projected Pharmaceutical Markets, 2015 Pharmaceutical Exports, 2003-2008 (US$ Millions) Pharmaceutical Imports, 2003-2008 (US$ Millions) Pharmaceutical Imports by Country/Region, 2008 (%) Pharmaceutical Balance of Trade, 2003-2008 (US$ Millions)

Radar Graph of the Pharmaceutical Market, 2010

Jordan: World Pharmaceutical Market Q2 2010

EXECUTIVE SUMMARY

Snapshot: Strategic Espicom Analysis

Snapshot: Key Data Projections

MACROENVIRONMENT

POLITICAL

ECONOMIC Projections

LEGAL

DEMOGRAPHIC Projections

Demographic Indicators Births

Deaths

Infant Deaths

Life Expectancy at Birth

EPIDEMIOLOGY

DISEASE BURDEN Leading Causes of Mortality

DISEASE PREVALENCE Communicable Diseases HIV/AIDS

Non-Communicable Diseases Cancer Incidence

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS

ORGANISATION

EXPENDITURE Projections

Latest Figures

INFRASTRUCTURE Hospital Infrastructure

Ambulatory Infrastructure

SERVICES Hospital Inpatient Services

Outpatient Services

WORKFORCE Projections

Physicians

Nurses

Dentists

Pharmacists

REGULATORY AFFAIRS

NATIONAL AUTHORITY Ministry of Health

MARKETING REGISTRATION National Procedures

IMPORT REGULATIONS

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

DRUG RETAILING

MARKET ANALYSIS

SIZE Projections

Current Size

Current Structure

PRODUCT DEVELOPMENT

MANUFACTURING Domestic Production

TRADE Exports

Imports

Balance of Trade

COMPETITION

TRADE ASSOCIATION Jordanian Association of Manufacturers of Pharmaceuticals & Medical Appliances

TRADE FAIRS Phar/MedExpo 2010

AUPAM Conference - Creating New Business Relationships

COMPANY INTELLIGENCE Domestic Producers Arab Centre for Pharmaceuticals and Chemicals

Dar Al Dawa

Hayat Pharmaceutical Industries

Hikma Pharmaceuticals

Jordanian Pharmaceuticals Manufacturing

Jordan River Pharmaceutical Industries

Jordan Sweden Medical and Sterilisation Company

Middle East Pharmaceutical Manufacturing Company

Pharma International

United Pharmaceutical Manufacturing

BIOLOGICS & BIOSIMILARS

PRODUCT DEVELOPMENT

COMPETITION Company Intelligence Al-Kindi Pharmaceutical Industries

AraGen Biotechnology

MONOJO

Competitive Strategies

CONCLUSIONS: OPPORTUNITIES & CHALLENGES

Strategic Espicom Analysis MACROENVIRONMENT

EPIDEMIOLOGY

HEALTHCARE

REGULATORY AFFAIRS

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET

COMPETITION

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

Radar Analysis

SWOT Analysis

DIRECTORY

GOVERNMENT ORGANISATIONS

PHARMACEUTICAL PRODUCERS Domestic Producers

Biotechnology Companies

TRADE ORGANISATION

LIST OF TABLES

Espicom Analysis of the Pharmaceutical Market, 2010 Key Data Projections, 2010-2015 Political Landscape, 2010 Regional Comparison of Projected Economies, 2015 Projected Economy, 2010-2015 Regional Comparison of Projected Demographics, 2015 Projected Demographics, 2010-2015 Population by Governorate, 2008 (000s) Summary of Demographic Indicators, 2008/2010 Demographic Indicators, 2003-2008 Notifiable Communicable Diseases & Conditions, 2004-2008 HIV/AIDS Patients, 1986-2008 Cancer Incidence by Sex, 2007 Regional Comparison of Projected Health Expenditure, 2015 Projected Health Expenditure, 2010-2015 Ministry of Health (MoH) Budget, 2004-2008 (JOD Millions) Hospitals & Beds, 2006 Hospital Beds by Sector, 2002-2006 MoH Health Centres, 2004-2008 MoH Hospital Activity, 2000-2008 Primary Healthcare Visits by Condition, 2004/2006 Regional Comparison of Projected Physicians, 2015 Projected Physicians, 2010-2015 Physicians by Sector, 2008 Nursing Staff by Category & Sector, 2008 Dentists by Sector, 2008 Pharmacists by Sector, 2008 Pharmacies, 2001-2008 Pharmacies by Governorate, 2005-2008 Regional Comparison of Projected Pharmaceutical Markets, 2015 Projected Pharmaceutical Market, 2010-2015 Pharmaceutical Market, 2010 Expenditure on Pharmaceuticals, 2000-2007 (JOD) Pharmaceutical Exports by Category, 2004-2008 (US$000s) Leading Destinations of Pharmaceuticals, 2008 (US$000s) Pharmaceutical Imports by Category, 2004-2008 (US$000s) Leading Suppliers of Raw Materials, 2008 (US$000s) Leading Suppliers of Antisera & Vaccines, 2008 (US$000s) Leading Suppliers of Medicaments, 2008 (US$000s) Balance of Pharmaceutical Trade, 2004-2008 (US$000s) Sales from 10 Jordanian Pharmaceutical Companies, 2007-2008 (JOD Millions) Members of JAPM, 2010 Hikma Pharmaceuticals' Mid-Year Results, 2009 (US$ Millions) Hikma Pharmaceuticals' Results, 2008 (US$ Millions) Hikma Pharmaceuticals' Results by Region, 2008 (US$ millions) Espicom Analysis of the Pharmaceutical Market, 2010 SWOT Analysis of the Pharmaceutical Market, 2010

LIST OF CHARTS

Regional Comparison of Projected Pharmaceutical Markets, 2015 Pharmaceutical Exports, 2000-2008 (US$ Millions) Change in Pharmaceutical Exports, 2001-2008 (%) Pharmaceutical Exports by Country/Region, 2008 (%) Pharmaceutical Imports, 2000-2008 (US$ Millions) Change in Pharmaceutical Imports, 2001-2008 (%) Pharmaceutical Imports by Country/Region, 2008 (%) Pharmaceutical Balance of Trade, 2000-2008 (US$ Millions) Radar Graph of the Pharmaceutical Market, 2010

Morocco: World Pharmaceutical Market Q2 2010

EXECUTIVE SUMMARY

Snapshot: Strategic Espicom Analysis

Snapshot: Key Data Projections

MACROENVIRONMENT

POLITICAL

ECONOMIC Projections

LEGAL Intellectual Property Rights

DEMOGRAPHIC Projections

Demographic Indicators Birth Rate

Death Rate

Infant Mortality

Maternal Mortality

Life Expectancy at Birth

EPIDEMIOLOGY

DISEASE BURDEN Leading Causes of Mortality

DISEASE PREVALENCE Communicable Diseases STIs & HIV/AIDS

Non-Communicable Diseases

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS

ORGANISATION Five Year Action Plan for the Health Sector (2008-2012)

New Planning Tools

EXPENDITURE Projections

Latest Figures Ministry of Health Budget, 2009

Health Insurance Compulsory Health Insurance Scheme

RAMED Scheme

INFRASTRUCTURE Hospital Infrastructure Capital Investment Programme, 2009

Ambulatory Infrastructure Public Ambulatory Infrastructure

Private Ambulatory Infrastructure

SERVICES Hospital Inpatient Services

WORKFORCE Projections

Latest Figures Physicians

Dentists

Nurses

Pharmacists

REGULATORY AFFAIRS

Pharmaceutical Regulation New Pharmaceutical Law

PRICING & REIMBURSEMENT

PRICING New Pharmaceutical Pricing System

Parliamentary Drug Pricing Report

Pharmaceutical Pricing System

Pharmaceutical Cost Structure

REIMBURSEMENT

DISTRIBUTION CHANNELS

MOH SUPPLIES DIVISION

WHOLESALING Cooper Maroc

Sophasud

RETAILING

MARKET ANALYSIS

SIZE Projections

Current Size

Current Structure Private Pharmacy Sales

CNOPS Pharmacy Sales

PRODUCT DEVELOPMENT

MANUFACTURING

TRADE Exports

Imports

Balance of Trade

COMPETITION

TRADE ASSOCIATIONS AMIP

MIS

TRADE FAIR Medical Expo

COMPANY INTELLIGENCE Local Manufacturers Afric-Phar

Bottu

Cooper Maroc

Laboratoire Galenica

Iberma

Laprophan

Pharmaceutical Institute

Polymedic

Promopharm

Sothema

Multinational Manufacturers Bayer Pharma Maroc

GlaxoSmithKline

Pfizer

sanofi-aventis

Servier

GENERIC PHARMACEUTICALS

PRICING New Pharmaceutical Pricing System

MARKET

BIOLOGICS & BIOSIMILARS

REGULATORY AFFAIRS Regulation of Biosimilars

MARKET SIZE Biosimilar Market

CONCLUSIONS: OPPORTUNITIES & CHALLENGES

Strategic Espicom Analysis MACROENVIRONMENT

EPIDEMIOLOGY

HEALTHCARE

REGULATORY AFFAIRS

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET

COMPETITION

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

Radar Analysis

SWOT Analysis

DIRECTORY

GOVERNMENT ORGANISATIONS

PRODUCERS Local Producers

Multinational Producers

TRADE ASSOCIATIONS

LIST OF TABLES

Espicom Analysis of the Pharmaceutical Market, 2010 Summary of Key Data Projections, 2010-2015 Political Landscape, 2010 Regional Comparison of Projected Economies, 2015 Projected Economy, 2010-2015 Regional Comparison of Projected Demographics, 2015 Projected Demographics, 2010-2015 Principal Demographic Indicators, 2002-2007 Reported Communicable Diseases, 2000-2007 Regional Comparison of Projected Health Expenditure, 2015 Projected Health Expenditure, 2010-2015 Health Expenditure, 2001-2008 Hospitals & Beds, 2007 Outpatient Facilities in the Public Sector, 2000-2007 Outpatient Facilities in the Private Sector, 2003-2007 Public Hospital Activity, 2001-2007 Activity of Public Hospital Surgical & Maternity Units, 2001-2007 University Hospital Activity, 2007 Regional Comparison of Projected Physicians, 2015 Projected Physicians, 2010-2015 Medical Personnel, 2000-2007 Retail Pharmacies by Region, 2006-2007 Regional Comparison of Projected Pharmaceutical Markets, 2015 Pharmaceutical Market Projections, 2010-2015 Pharmaceutical Market, 2010 Pharmaceutical Market by Sector at Retail Prices, 2008 Private Pharmacy Sales at Manufacturers' Prices, 1998-2009 Private Pharmacy Sales at Manufacturers' Prices, 1998-2009 (DH Millions) CNOPS Pharmacy Sales, 2000-2008 CNOPS Branded & Generic Pharmacy Sales, 2006-2008 (DH Million) Production Units & Direct Employees, 1965-2008 Pharmaceutical Production, 1999-2005 Pharmaceutical Production by Type, 2003/2005 Key Figures for Pharmaceutical Producers, 2003-2005 Pharmaceutical Exports by Category, 2004-2008 (US$ Million) Pharmaceutical Exports by Country/Region, 2008 (US$000s) Pharmaceutical Imports by Category, 2004-2008 (US$000s) Imports of Raw Materials by Country/Region, 2008 (US$000s) Imports of Antisera & Vaccines by Country/Region, 2008 (US$000s) Imports of Medicaments by Country/Region, 2008 (US$000s) Balance of Pharmaceutical Trade, 2004-2008 (US$000s) Members of AMIP, 2010 Members of MIS, 2010 Espicom Analysis of the Pharmaceutical Market, 2010 SWOT Analysis of the Pharmaceutical Market, 2010

LIST OF CHARTS

Ministry of Health' s Budget by Sector, 1995-2009 (DH 000s) Regional Comparison of Projected Pharmaceutical Markets, 2015 Private Pharmacy Sales Value by Principal Therapeutic Categories, 2007 (%) Private Pharmacy Sales Volume by Principal Therapeutic Categories, 2007 (%) Pharmaceutical Exports, 1997-2008 Pharmaceutical Imports, 1997-2008 Pharmaceutical Imports by Leading Country/Region, 2008 (%) Balance of Pharmaceutical Trade, 2000-2008 (US$ Millions) Branded & Generic Pharmacy Sales Volume, 2001-2007 Radar Graph of the Pharmaceutical Market, 2010

Saudi Arabia: Pharmaceutical Market Intelligence Report Quarter II 2010

EXECUTIVE SUMMARY

Pharmaceutical Market Analysis

Size

Market Structure Pharmacy Sector

Generics Sector

Projections & Outlook

Imports

Domestic Manufacturing Local Pharmaceutical Manufacturers Jamjoom

Riyadh Pharma

SAJAPHCO

SPIMACO

Tabuk

Foreign Pharmaceutical Manufacturers GlaxoSmithKline

Hikma

Biotechnology Manufacturers Jeddah BioCity

Stem Cell Research

Exports

Balance of Trade

Research & Development

Pharmaceutical Regulatory Analysis

Pharmaceutical Regulation

Pricing & Reimbursement Price Cuts

GCC Plans to Standardise Price of Medicines

Intellectual Property Rights Background

USTR Position

Pharmaceutical Distribution

Drug Wholesaling Abdulrehman Algosaibi

Arabian Medical Hospital Supply Company

Arabian Medicare

Banaja

Tamer Group

Drug Retailing

Healthcare Analysis

Demographics Population

Demographic Indicators Birth Rate

Death Rate

Infant Mortality

Life Expectancy at Birth

Public Health Causes of Death

Communicable Diseases

Non-communicable Diseases

To order this report:

Pharmaceutical Industry: The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015

Pharmaceutical Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Tue, 31 Aug 2010 16:45:18 +0000

Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

PR Newswire

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

http://www.reportlinker.com/p0286296/Urological-Disorders-Therapeutics-to-2016---Increasing-Awareness-and-Aging-Population-will-Drive-the-Benign-Prostatic-Hyperplasia-and-Urinary-Incontinence-Markets.html

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Summary

GBI Research's Therapeutic Analysis report, "Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets", provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. GBI Research finds that the urological disorders market will continue to grow moderately, largely due to increase in aging population and increase in awareness of indications such as UI, BPH and UTI. The prime reason for slow growth of the market will be a series of patent expiries of the top selling blockbusters across all the markets. Particularly in BPH, the entry of generics coupled with the patent expirations of Flomax, Uroxatral (in US) and Avodart, three of the best selling drugs in the BPH market, is expected to pull down the market in terms of value in the future. However, the patent expiries will not result in significant market value loss due to the low price differential between branded and generics.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

- Annualized market data for the urological disorders market from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading therapeutic segments, including Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI).

- Analysis of the urological disorders market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.

- Market characterization of the urological disorders market, including market size, annual cost of therapy and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc, Novexel SA, Eli Lilly and Company, GSK, Sanofi-- Aventis, Johnson and Johnson and Protox Therapeutics, Inc.

- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global urological disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 7

2 Global Urological Disorders Market: Introduction 10

2.1 GBI Research Report Guidance 11

3 Global Urological Disorders Market: Market Overview 12

3.1 Introduction 12

3.2 Revenue Forecasts for the Global Urological Disorders Market 13

3.2.1 Sales Value 13

3.2.2 Annual Cost of Therapy 14

3.2.3 Treatment Usage Patterns 15

3.2.4 Generics' Share in the Global Urological Disorders Market 20

3.3 Urological Disorders Market Drivers 22

3.3.1 Steady Increase in the UI and BPH Prevalence Population 22

3.3.2 Rapid Uptake of Branded Products due to Better Efficacy in BPH 22

3.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable 22

3.4 Urological Disorders Market Restraints 23

3.4.1 Unwillingness to Seek Medical Help for UI 23

3.4.2 Patent Expiries of Major Blockbusters Including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenues 23

3.4.3 Non Pharmacological Therapy Recommended for UI and BPH 23

4 Global Urological Disorders Market: Therapeutic Landscape 24

4.1 Benign Prostatic Hyperplasia Market 24

4.1.1 Introduction 24

4.1.2 Sales Value 24

4.1.3 Annual Cost of Therapy 26

4.1.4 Treatment Usage Patterns 27

4.1.5 Market Share by Geography 32

4.1.6 Generics' Share of the Global BPH Market 35

4.2 Urinary Incontinence (UI) Market 36

4.2.1 Introduction 36

4.2.2 Sales Value 37

4.2.3 Annual Cost of Therapy 39

4.2.4 Treatment Usage Patterns 40

4.2.5 Market Share by Geography 45

4.2.6 Generics' Share in the Global UI Market 49

4.3 Urinary Tract Infections Market 51

4.3.1 Introduction 51

4.3.2 Sales Value 51

4.3.3 Annual Cost of Therapy 53

4.3.4 Treatment Usage Patterns 54

4.3.5 Market Share by Geography 59

4.3.6 Generics' Share of the Global UTI Market 62

5 Global Urological Disorders Market: Geographical Landscape 64

5.1 Geographical Break-up 64

5.2 The US 67

5.2.1 Sales Value 67

5.2.2 Annual Cost of Therapy 68

5.2.3 Treatment Usage Patterns 69

5.3 Top Five Countries in Europe 75

5.3.1 Sales Value 75

5.3.2 Annual Cost of Therapy 76

5.3.3 Treatment Usage Patterns 77

5.4 Japan 83

5.4.1 Sales Value 83

5.4.2 Annual Cost of Therapy 84

5.4.3 Treatment Usage Patterns 85

6 Global Urological Disorders Market: Pipeline Analysis 90

6.1 Introduction 90

6.1.1 Research and Development Pipeline – UI 91

6.1.2 Research and Development Pipeline – BPH 93

6.1.3 Research and Development Pipeline – UTI 95

6.2 Profiles of Key Late-Stage Drugs in the Urological Disorders Market 97

6.2.1 Botulinum Toxin A 97

6.2.2 YM178 98

6.2.3 NX-1207 98

6.2.4 PRX302 99

6.2.5 NXL104/ceftazidime 100

7 Global Urological Disorders Market: Competitive Landscape 101

7.1 Market Share Analysis: Urological Disorders 101

7.2 Competitive Profiling 103

7.2.1 Astellas Pharma 103

7.2.2 Johnson and Johnson (J&J) 104

7.2.3 Pfizer 106

7.2.4 GlaxoSmithKilne (GSK) 107

7.2.5 Sanofi-Aventis 108

8 Global Urological Disorders Market: Strategic Consolidations 110

8.1 Overview 110

8.1.1 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 112

8.1.2 Actavis Group Acquires Floxapen from GlaxoSmithKline in May 2007 112

8.1.3 Biofusion Acquires Minority Stake in Muscagen in November 2006 112

8.1.4 Eli Lilly Reacquires Rights to Yentreve from Boehringer Ingelheim in February 2006 112

8.1.5 Odyssey Pharmaceuticals Sells SANCTURA to Esprit Pharma in May 2005 112

8.1.6 Ardana Bioscience Acquires Rights to Teverelix from AEterna Zentaris in April 2004 112

8.2 R&D Licensing Agreements 113

8.2.1 Deals by Indication 113

8.2.2 Deals by Phase 114

8.2.3 Deals by Geography 114

8.2.4 Deals by Licensing Type 115

8.2.5 Deals by Value ($) 115

8.2.6 Phase I 116

8.2.7 Phase II 117

8.2.8 Approved 118

9 Global Urological Disorders Market: Appendix 120

9.1 Market Definitions 120

9.2 Abbreviations 120

9.3 Research Methodology 121

9.3.1 Coverage 121

9.3.2 Secondary Research 121

9.3.3 Primary Research 122

9.3.4 Forecasts 122

9.3.5 Expert Panel Validation 124

9.4 Contact Us 125

9.5 Disclaimer 125

9.6 Sources 125

1.1 List of Tables

Table 1: Urological Disorders Market, Global, Sales Value ($bn), 2001–2009 13

Table 2: Urological Disorders Market, Global, Sales Value ($bn), 2009–2016 13

Table 3: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2001–2009 14

Table 4: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2009–2016 15

Table 5: Urological Disorders Market, Global, Treatment Usage Patterns (million), 2001–2009 16

Table 6: Urological Disorders Market, Global, Treatment Usage Patterns (million), 2009–2016 16

Table 7: Urological Disorders Market, Global, Branded Vs Generic Drugs ($bn), 2001–2009 21

Table 8: Urological Disorders Market, Global, Branded Vs Generic Drugs ($bn), 2009–2016 21

Table 9: Urological Disorders Market, Global, BPH Sales Value ($bn), 2001–2009 25

Table 10: Urological Disorders Market, Global, BPH Sales Value ($bn), 2009–2016 25

Table 11: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2001–2009 26

Table 12: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2009–2016 27

Table 13: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2001–2009 27

Table 14: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2009–2016 28

Table 15: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2001–2009 33

Table 16: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2009–2016 34

Table 17: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2001–2009 35

Table 18: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2009–2016 36

Table 19: Urological Disorders Market, Global, UI Sales Value ($bn), 2001–2009 38

Table 20: Urological Disorders Market, Global, UI Sales Value ($bn), 2009–2016 38

Table 21: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2001–2009 39

Table 22: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2009–2016 39

Table 23: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2001–2009 40

Table 24: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2009–2016 41

Table 25: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2001–2009 47

Table 26: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2009–2016 47

Table 27: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2001–2009 49

Table 28: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2009–2016 50

Table 29: Urological Disorders Market, Global, UTI Sales Value ($bn), 2001–2009 52

Table 30: Urological Disorders Market, Global, UTI Sales Value ($bn), 2009–2016 52

Table 31: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2001–2009 53

Table 32: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2009–2016 53

Table 33: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2001–2009 54

Table 34: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2009–2016 55

Table 35: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2001–2009 60

Table 36: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2009–2016 61

Table 37: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2001–2009 62

Table 38: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2009–2016 62

Table 39: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2001–2009 65

Table 40: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2009–2016 65

Table 41: Urological Disorders Market, US, Sales Value ($bn), 2001–2009 67

Table 42: Urological Disorders Market, US, Sales Value ($bn), 2009–2016 68

Table 43: Urological Disorders Market, US, Annual Cost of Therapy ($), 2001–2009 68

Table 44: Urological Disorders Market, US, Annual Cost of Therapy ($), 2009–2016 69

Table 45: Urological Disorders Market, US, Treatment Usage Patterns (million), 2001–2009 70

Table 46: Urological Disorders Market, US, Treatment Usage Patterns (million), 2009–2016 70

Table 47: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2009 75

Table 48: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2009–2016 76

Table 49: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2009 77

Table 50: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016 77

Table 51: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2001–2009 78

Table 52: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2009–2016 78

Table 53: Urological Disorders Market, Japan, Sales Value ($bn), 2001–2009 83

Table 54: Urological Disorders Market, Japan, Sales Value ($bn), 2009–2016 84

Table 55: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2009 84

Table 56: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2009–2016 84

Table 57: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2009 85

Table 58: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2009–2016 86

Table 59: Urological Disorders Market, Global, R&D Pipeline by Phase in UI Market, AUG 2010 92

Table 60: Urological Disorders Market, Global, R&D Pipeline by Phase in BPH Market, AUG 2010 94

Table 61: Urological Disorders Market, Global, R&D Pipeline by Phase in UTI Market, AUG 2010 96

Table 62: Urological Disorders Market, Global, Major M&A Deals, 2004-2009 111

Table 63: Urological Disorders Market, Global, Licensing Agreements for Drugs in Phase I Stage, 2004 116

Table 64: Urological Disorders Market, Global, Licensing Agreements for Drugs in Phase II Stage, 2004–2010 117

Table 65: Urological Disorders Market, Global, Licensing Agreements for Approved Drugs, 2008–2010 118

1.2 List of Figures

Figure 1: Urological Disorders Market, Global, Drivers and Restraints, 2009 11

Figure 2: Urological Disorders Market, Global, Sales Value ($bn), 2001–2016 12

Figure 3: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2001–2016 13

Figure 4: Urological Disorders Market, Global, Therapeutic Usage Patterns (million), 2001–2016 14

Figure 5: Urological Disorders Market, Global, Diseased Population (million), 2001–2016 16

Figure 6: Urological Disorders Market, Global, Treatment Seeking Population (million), 2001–2016 17

Figure 7: Urological Disorders Market, Global, Diagnosis Population (million), 2001–2016 18

Figure 8: Urological Disorders Market, Global, Prescription Population (million), 2001–2016 19

Figure 9: Urological Disorders Market, Global, Branded Vs Generics ($bn), 2001–2016 20

Figure 10: Urological Disorders Market, Global, Market Indicators, 2009 21

Figure 11: Urological Disorders Market, Global, BPH Sales Value ($bn), 2001–2016 24

Figure 12: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2001–2016 25

Figure 13: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2001–2016 26

Figure 14: Urological Disorders Market, Global, BPH Diseased Population (million), 2001–2016 27

Figure 15: Urological Disorders Market, Global, BPH Treatment Seeking Population (million), 2001–2016 28

Figure 16: Urological Disorders Market, Global, BPH Diagnosis Population (million), 2001–2016 29

Figure 17: Urological Disorders Market, Global, BPH Prescription Population (million), 2001–2016 30

Figure 18: Urological Disorders Market, Global, BPH Market Segmentation by Geography (%), 2009 and 2016 31

Figure 19: Urological Disorders Market, Global, BPH Market in the Top Five Countries in Europe (%), 2009 and 2016 31

Figure 20: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2001–2016 32

Figure 21: Urological Disorders Market, Global, BPH Market, Geography Benchmarking, 2009 33

Figure 22: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2001–2016 34

Figure 23: Urological Disorders Market, Global, BPH Market, Generics Share (%), 2009 and 2016 35

Figure 24: Urological Disorders Market, Global, UI Sales Value ($bn), 2001–2016 37

Figure 25: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2001–2016 38

Figure 26: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2001–2016 39

Figure 27:Urological Disorders Market, Global, UI Diseased Population (million), 2001–2016 40

Figure 28:Urological Disorders Market, Global, UI Treatment Seeking Population (million), 2001–2016 41

Figure 29:Urological Disorders Market, Global, UI Diagnosis Population (million), 2001–2016 42

Figure 30: Urological Disorders Market, Global, UI Prescription Population (million), 2001–2016 43

Figure 31: Urological Disorders Market, Global, UI Market Segmentation by Geography (%), 2009 and 2016 44

Figure 32: Urological Disorders Market, Global, UI Market in the Top Five Countries in Europe (%), 2009 and 2016 44

Figure 33: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2001–2016 45

Figure 34: Urological Disorders Market, Global, UI Market, Geography Benchmarking, 2009 47

Figure 35: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2001–2016 48

Figure 36: Urological Disorders Market, Global, UI Market, Generics Share (%), 2009 and 2016 49

Figure 37: Urological Disorders Market, Global, UTI Sales Value ($bn), 2001–2016 51

Figure 38: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2001–2016 52

Figure 39: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2001–2016 53

Figure 40: Urological Disorders Market, Global, UTI Diseased Population (million), 2001–2016 54

Figure 41: Urological Disorders Market, Global, UTI Treatment Seeking Population (million), 2001–2016 55

Figure 42: Urological Disorders Market, Global, UTI Diagnosis Population (million), 2001–2016 56

Figure 43: Urological Disorders Market, Global, UTI Prescription Population (millions), 2001–2016 57

Figure 44: Urological Disorders Market, Global, UTI Market Segmentation by Geography (%), 2009 and 2016 58

Figure 45: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2001–2016 59

Figure 46: Urological Disorders Market, Global, UTI Market, Geography Benchmarking, 2009 60

Figure 47: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2001–2016 61

Figure 48: Urological Disorders Market, Global, UTI Market, Generics Share (%), 2009 and 2016 62

Figure 49: Urological Disorders Market, Global, Market Share by Geography (%), 2009 and 2016 63

Figure 50: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2001–2016 64

Figure 51: Urological Disorders Market, Global, Geography Benchmarking, 2009 and 2016 65

Figure 52: Urological Disorders Market, US, Sales Value ($bn), 2001–2016 66

Figure 53: Urological Disorders Market, US, Annual Cost of Therapy ($), 2001–2016 67

Figure 54: Urological Disorders Market, US, Treatment Usage Patterns (million), 2001–2016 69

Figure 55: Urological Disorders Market, US, Diseased Population (million), 2001–2016 70

Figure 56: Urological Disorders Market, US, Treatment Seeking Population (million), 2001–2016 71

Figure 57: Urological Disorders Market, US, Diagnosis Population (million), 2001–2016 72

Figure 58: Urological Disorders Market, US, Prescription Population (million), 2001–2016 73

Figure 59: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2016 74

Figure 60: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2016 75

Figure 61: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2001–2016 76

Figure 62: Urological Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2001–2016 78

Figure 63: Urological Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2001–2016 79

Figure 64: Urological Disorders Market, Top Five Countries in Europe, Diagnosis Population (million), 2001–2016 80

Figure 65: Urological Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2001–2016 81

Figure 66: Urological Disorders Market, Japan, Sales Value ($bn), 2001–2016 82

Figure 67: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2016 83

Figure 68: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2016 84

Figure 69: Urological Disorders Market, Japan, Diseased Population (million), 2001–2016 85

Figure 70: Urological Disorders Market, Japan, Treatment Seeking Population (million), 2001–2016 86

Figure 71: Urological Disorders Market, Japan, Diagnosed Population (million), 2001–2016 87

Figure 72: Urological Disorders Market, Japan, Prescription Population (million), 2001–2016 88

Figure 73: Urological Disorders Market, Global, R&D Pipeline by Indication (%), AUG 2010 89

Figure 74: Urological Disorders Market, Global, R&D Pipeline by Phase (%), AUG 2010 90

Figure 75: Urological Disorders Market, Global, R&D Pipeline by Phase in UI Market (%), AUG 2010 92

Figure 76: Urological Disorders Market, Global, R&D Pipeline by Phase in BPH Market (%), AUG 2010 94

Figure 77: Urological Disorders Market, Global, R&D Pipeline by Phase in UTI Market (%), AUG 2010 95

Figure 78: Urological Disorders Market, Global, Market Share of Top Manufacturers (%), 2009 100

Figure 79: Urological Disorders Market, Global, Revenue of Top Five Players ($m), 2007–2009 101

Figure 80: Urological Disorders Market, Global, Competitive Analysis of Top Five Players, Market Share and CAGR (%), 2007–2009 102

Figure 81: Urological Disorders Market, Global, SWOT- Astellas Pharma, 2010 103

Figure 82: Urological Disorders Market, Global, SWOT- Johnson & Johnson, 2010 105

Figure 83: Urological Disorders Market, Global, SWOT- Pfizer, 2010 106

Figure 84: Urological Disorders Market, Global, SWOT- GlaxoSmithKline, 2010 107

Figure 85: Urological Disorders Market, Global, SWOT- Sanofi-Aventis, 2010 108

Figure 86: Urological Disorders Market, Global, M&A Deals by Indication (%), 2009 109

Figure 87: Urological Disorders Market, Global, Major Licensing Agreements By Indication (%), 2004–2010 112

Figure 88: Urological Disorders Market, Global, Major Licensing Agreements By Phase (%), 2005–2010 113

Figure 89: Urological Disorders Market, Global, Major Licensing Agreements By Geography (%), 2004–2010 113

Figure 90: Urological Disorders Market, Global, Major Licensing Agreements By Licensing Type (%), 2004–2010 114

Figure 91: Urological Disorders Market, Global, Major Licensing Agreements By Deal Value (%), 2004–2010 114

Figure 92: GBI Research Market Forecasting Model 123

Companies mentioned

Astellas Pharma

Johnson and Johnson (J&J)

Pfizer

GlaxoSmithKilne (GSK)

Sanofi-Aventis

To order this report:

Pathology Industry: Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Pathology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Reportlinker Adds Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market

Tue, 31 Aug 2010 15:43:24 +0000

Reportlinker Adds Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market

PR Newswire

NEW YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0286298/Mens-Health-Therapeutics-Market-to-2016---Selective-Serotonin-Reuptake-Inhibitors-Hormone-Replacement-Therapy-and-Phosphodiesterase-Type-5-Inhibitors-Will-Dominate-the-Market.html

Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market

Summary

GBI Research has released its pharmaceutical industry research "Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors will Dominate the Market". The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global men's health market. The report analyzes the markets for men's health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the men's health market will continue to grow moderately. The prime reason for stagnancy will be the patent expiry of a top selling blockbuster, Viagra. The overall men's health market is driven by the launch of late-stage pipeline candidates and the steady increase in prevalence and prescription population. The erectile dysfunction market controls a major portion of the men's health market. In 2009 it accounted for 81% of the total men's health market. Male hypogonadism accounts for 18% of the total market size. The premature ejaculation market represents a small portion of the total men's health market. The premature ejaculation market has the highest level of unmet needs because it does not have any FDA approved products. However, it will grow at a higher rate during the forecast period compared to the erectile dysfunction and male hypogonadism market. This is because the premature ejaculation market will see the launch of new drugs in the near future. In 2009, the global men's health market was estimated at $4,019m.

Scope

- Annualized market data for the men's health market from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism and premature ejaculation.

- Analysis of the men's health market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.

- Market characterization of the men's health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Abbott Laboratories, Endo-Pharmaceuticals Holding Inc., Janssen-Cilag EMEA, VIVUS Inc., Auxilium Pharmaceuticals, Inc., APP Pharmaceuticals, Inc, Columbia Laboratories, Inc., Watson Pharmaceuticals, Inc. and Valeant Pharmaceuticals International.

- Key M&A activities, licensing agreements, that have taken place in 2009 in the global men's health market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 9

2 Global Men's Health Therapeutics Market: Scope of Research 11

2.1 Overview 11

2.2 GBI Research Report Guidance 11

3 Global Men's Health Therapeutics Market: Market Characterization 12

3.1 Introduction 12

3.2 Market Forecasts 13

3.3 Annual Cost of Treatment 14

3.4 Treatment Usage Patterns 15

3.4.1 Diseased Population 17

3.4.2 Treatment Seeking Population 18

3.4.3 Diagnosis Population 19

3.4.4 Prescription Population 21

3.5 Market Share by Geography 22

3.6 Generics' Share in the Global Men's Health Market 23

3.7 Men's Health Market Drivers 24

3.7.1 Steady Increase in the Prevalence Population 24

3.7.2 Launch of late-stage pipeline candidates 24

3.7.3 Steady Increase in the Prescription Population 25

3.8 Men's Health Market Restraints 25

3.8.1 Low Treatment Seeking Rate 25

3.8.2 Low Diagnosis Rate 25

3.8.3 Patent Expiry of a Major Blockbuster 25

4 Global Erectile Dysfunction Therapeutics Market 26

4.1 Market Overview 26

4.2 Market Forecasts 27

4.3 Annual Cost of Treatment 28

4.4 Treatment Usage Patterns 29

4.4.1 Diseased Population 31

4.4.2 Treatment Seeking Population 32

4.4.3 Diagnosis Population 33

4.4.4 Prescription Population 35

4.5 Market Share by Geography 36

4.6 Product Analysis 37

4.6.1 Viagra (sildenafil citrate) 37

4.6.2 Cialis (tadalafil) 37

4.6.3 Levitra (verdenafil HCL) 37

4.6.4 Caverject (Alprostadil) 38

4.6.5 Muse (alprostadil) 38

5 Global Male Hypogonadism Therapeutics Market 39

5.1 Market Overview 39

5.2 Market Forecasts 40

5.3 Annual Cost of Treatment 41

5.4 Treatment Usage Patterns 42

5.4.1 Diseased Population 44

5.4.2 Treatment Seeking Population 45

5.4.3 Diagnosis Population 46

5.4.4 Prescription Population 48

5.5 Market Share by Geography 49

5.6 Product Analysis 50

5.6.1 Gel (AndroGel, Testim): 50

5.6.2 Injections (Depo-Testosterone, Delatestryl): 50

5.6.3 Transdermal Patch (Androderm, Testoderm) 50

5.6.4 Buccal Tablet (Striant) 50

5.6.5 Pellet Implant 50

6 Global Premature Ejaculation (PE) Therapeutics Market 51

6.1 Market Overview 51

6.2 Market Forecasts 51

6.3 Annual Cost of Treatment 53

6.4 Treatment Usage Patterns 54

6.4.1 Diseased Population 56

6.4.2 Treatment Seeking Population 57

6.4.3 Diagnosis Population 59

6.4.4 Prescription Population 60

6.5 Market Share by Geography 61

6.6 Product Analysis 62

6.6.1 Fluoxetine (Prozac, Sarafem) 62

6.6.2 Paroxetine (Paxil) 63

6.6.3 Sertraline (Zoloft) 63

6.6.4 Dapoxetine (Priligy) 63

6.6.5 Clomipramine (Anafranil) 63

6.6.6 Lidocaine/prilocaine cream (EMLA cream) 63

7 Global Men's Health Market: Geographical Landscape 64

7.1 Market Forecasts by Geography 64

7.2 The US 66

7.2.1 Market Forecasts 66

7.2.2 Annual Cost of Treatment 68

7.2.3 Treatment Usage Patterns 69

7.3 Top Five Countries in Europe 76

7.3.1 Market Forecasts 76

7.3.2 Annual Cost of Treatment 78

7.3.3 Treatment Usage Patterns 79

7.4 Japan 86

7.4.1 Market Forecasts 86

7.4.2 Annual Cost of Treatment 87

7.4.3 Treatment Usage Patterns 89

8 Global Men's Health Market: Pipeline Analysis 97

8.1 Introduction 97

8.1.1 Research and Development Pipeline – Erectile Dysfunction 99

8.1.2 Research and Development Pipeline – Premature Ejaculation 100

8.1.3 Research and Development Pipeline – Male Hypogonadism 101

8.2 Men's Health Pipeline – Pipeline by Clinical Phases of Development 102

8.2.1 Erectile Dysfunction Pipeline – Pipeline by Clinical Phases of Development 102

8.2.2 Premature Ejaculation Pipeline – Pipeline by Clinical Phases of Development 103

8.2.3 Male Hypogonadism Pipeline – Pipeline by Clinical Phases of Development 104

8.3 Profiles of Key Late-Stage Drugs in the Men's Health Market 106

8.3.1 Profiles of Key Late-Stage Drugs in the Erectile Dysfunction Market 106

8.3.2 Profiles of Key Late-Stage Drugs in the Premature Ejaculation Market 106

8.3.3 Profiles of Key Late-Stage Drugs in the Male Hypogonadism Market 107

9 Global Men's Health Market: Competitive Landscape 109

9.1 Overview 109

9.2 Competitive Profiling 109

9.2.1 Pfizer Inc. 109

9.2.2 Eli Lilly and Company 110

9.2.3 GlaxoSmithKline, Inc 111

9.2.4 Abbott Laboratories (Abbott acquired Solvay Pharmaceuticals) 112

9.2.5 Endo Pharmaceuticals Holding Inc. 113

9.2.6 Janssen-Cilag EMEA 114

9.2.7 VIVUS, Inc. 115

9.2.8 Auxilium Pharmaceuticals, Inc. 116

9.2.9 APP Pharmaceuticals (acquired by Fresenius Kabi Pharmaceuticals) 117

9.2.10 Columbia Laboratories, Inc. 118

9.2.11 Watson Pharmaceutical, Inc. 119

9.2.12 Valeant Pharmaceuticals International 120

10 Global Men's Health Market: Strategic Consolidations 122

10.1 Mergers and Acquisitions 122

10.1.1 Overview 122

10.1.2 Summary of Mergers and Acquisitions 125

10.2 R&D Licensing Agreements 128

10.2.1 Deals by Indication 128

10.2.2 Deals by Geography 129

10.2.3 Summary of Licensing Deals 129

11 Global Men's Health Therapeutics Market : Appendix 133

11.1 Market Definitions 133

11.2 Abbreviations 133

11.3 Research Methodology 134

11.3.1 Coverage 134

11.3.2 Secondary Research 134

11.3.3 Primary Research 134

11.3.4 Forecasts 135

11.3.5 Expert Panel Validation 137

11.4 Contact Us 138

11.5 Disclaimer 138

11.6 Sources 138

1.1 List of Tables

Table 1: Men's Health Therapeutics Market, Global, Revenue ($m), 2001–2009 13

Table 2: Men's Health Therapeutics Market, Global, Revenue ($m), 2009–2016 14

Table 3: Men's Health Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2009 14

Table 4: Men's Health Therapeutics Market, Global, Annual Cost of Treatment ($), 2009–2016 15

Table 5: Men's Health Therapeutics Market, Global, Usage Patterns, 2001–2009 16

Table 6: Men's Health Therapeutics Market, Global, Usage Patterns, 2009–2016 16

Table 7: Men's Health Therapeutics Market, Global, Diseased Population, 2001–2009 17

Table 8: Men's Health Therapeutics Market, Global, Diseased Population, 2009–2016 17

Table 9: Men's Health Therapeutics Market, Global, Treatment Seeking Population, 2001–2009 18

Table 10: Men's Health Therapeutics Market, Global, Treatment Seeking Population, 2009–2016 19

Table 11: Men's Health Therapeutics Market, Global, Diagnosis Population, 2001–2009 20

Table 12: Men's Health Therapeutics Market, Global, Diagnosis Population, 2009–2016 20

Table 13: Men's Health Therapeutics Market, Global, Prescription Population, 2001–2009 21

Table 14: Men's Health Therapeutics Market, Global, Prescription Population, 2009–2016 21

Table 15: Men's Health Therapeutics Market, Global, Market Drivers, 2010 24

Table 16: Men's Health Therapeutics Market, Global, Market Restraints, 2010 25

Table 17: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2001–2009 27

Table 18: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2009–2016 28

Table 19: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2009 28

Table 20: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment ($), 2009–2016 29

Table 21: Erectile Dysfunction Therapeutics Market, Global, Usage Patterns, 2001–2009 30

Table 22: Erectile Dysfunction Therapeutics Market, Global, Usage Patterns, 2009–2016 30

Table 23: Erectile Dysfunction Therapeutics Market, Global, Diseased Population, 2001–2009 31

Table 24: Erectile Dysfunction Therapeutics Market, Global, Diseased Population, 2009–2016 32

Table 25: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population, 2001–2009 33

Table 26: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population, 2009–2016 33

Table 27: Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population, 2001–2009 34

Table 28: Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population, 2009–2016 34

Table 29: Erectile Dysfunction Therapeutics Market, Global, Prescription Population, 2001–2009 35

Table 30: Erectile Dysfunction Therapeutics Market, Global, Prescription Population, 2009–2016 35

Table 31: Male Hypogonadism Therapeutics Market, Global, Revenue ($m), 2001–2009 40

Table 32: Male Hypogonadism Therapeutics Market, Global, Revenue ($m), 2009–2016 40

Table 33: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2009 41

Table 34: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment ($), 2009–2016 42

Table 35: Male Hypogonadism Therapeutics Market, Global, Usage Patterns, 2001–2009 43

Table 36: Male Hypogonadism Therapeutics Market, Global, Usage Patterns, 2009–2016 43

Table 37: Male Hypogonadism Therapeutics Market, Global, Diseased Population, 2001–2009 44

Table 38: Male Hypogonadism Therapeutics Market, Global, Diseased Population, 2009–2016 44

Table 39: Male Hypogonadism Therapeutics Market, Global, Treatment Seeking Population, 2001–2009 45

Table 40: Male Hypogonadism Therapeutics Market, Global, Treatment Seeking Population, 2009–2016 46

Table 41: Male Hypogonadism Therapeutics Market, Global, Diagnosis Population, 2001–2009 47

Table 42: Male Hypogonadism Therapeutics Market, Global, Diagnosis Population, 2009–2016 47

Table 43: Male Hypogonadism Therapeutics Market, Global, Prescription Population, 2001–2009 48

Table 44: Male Hypogonadism Therapeutics Market, Global, Prescription Population, 2009–2016 48

Table 45: Premature Ejaculation Therapeutics Market, Global, Revenue ($m), 2001–2009 52

Table 46: Premature Ejaculation Therapeutics Market, Global, Revenue ($m), 2009–2016 52

Table 47: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2009 53

Table 48: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment ($), 2009–2016 53

Table 49: Premature Ejaculation Therapeutics Market, Global, Usage Patterns, 2001–2009 55

Table 50: Premature Ejaculation Therapeutics Market, Global, Usage Patterns, 2009–2016 55

Table 51: Premature Ejaculation Therapeutics Market, Global, Diseased Population, 2001–2009 56

Table 52: Premature Ejaculation Therapeutics Market, Global, Diseased Population, 2009–2016 56

Table 53: Premature Ejaculation Therapeutics Market, Global, Treatment Seeking Population, 2001–2009 58

Table 54: Premature Ejaculation Therapeutics Market, Global, Treatment Seeking Population, 2009–2016 58

Table 55: Premature Ejaculation Therapeutics Market, Global, Diagnosis Population, 2001–2009 59

Table 56: Premature Ejaculation Therapeutics Market, Global, Diagnosis Population, 2009–2016 59

Table 57: Premature Ejaculation Therapeutics Market, Global, Prescription Population, 2001–2009 61

Table 58: Premature Ejaculation Therapeutics Market, Global, Prescription Population, 2009–2016 61

Table 59: Men's Health Market, Global, Sales Value by Geography ($m), 2001–2009 64

Table 60: Men's Health Market, Global, Sales Value by Geography ($m), 2009–2016 65

Table 61: Men's Health Therapeutics Market, The US, Revenue ($m), 2001–2009 67

Table 62: Men's Health Therapeutics Market, The US, Revenue ($m), 2009–2016 67

Table 63: Men's Health Therapeutics Market, The US, Annual Cost of Treatment ($) , 2001–2009 68

Table 64: Men's Health Therapeutics Market, The US, Annual Cost of Treatment ($), 2009–2016 68

Table 65: Men's Health Therapeutics Market, The US, Usage Patterns, 2001–2009 70

Table 66: Men's Health Therapeutics Market, The US, Usage Patterns, 2009–2016 70

Table 67: Men's Health Therapeutics Market, The US, Diseased Population, 2001–2009 71

Table 68: Men's Health Therapeutics Market, The US, Diseased Population, 2009–2016 71

Table 69: Men's Health Therapeutics Market, The US, Treatment Seeking Population, 2001–2009 72

Table 70: Men's Health Therapeutics Market, The US, Treatment Seeking Population, 2009–2016 73

Table 71: Men's Health Therapeutics Market, The US, Diagnosis Population, 2001–2009 74

Table 72: Men's Health Therapeutics Market, The US, Diagnosis Population, 2009–2016 74

Table 73: Men's Health Therapeutics Market, The US, Prescription Population, 2001–2009 75

Table 74: Men's Health Therapeutics Market, The US, Prescription Population, 2009–2016 75

Table 75: Men's Health Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2001–2009 77

Table 76: Men's Health Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2009–2016 77

Table 77: Men's Health Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($) , 2001–2009 78

Table 78: Men's Health Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2009–2016 78

Table 79: Men's Health Therapeutics Market, Top Five Countries in Europe, Usage Patterns, 2001–2009 80

Table 80: Men's Health Therapeutics Market, Top Five Countries in Europe, Usage Patterns, 2009–2016 80

Table 81: Men's Health Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2001–2009 81

Table 82: Men's Health Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2009–2016 81

Table 83: Men's Health Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2001–2009 82

Table 84: Men's Health Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2009–2016 83

Table 85: Men's Health Therapeutics Market, Top Five Countries in Europe, Diagnosis Population, 2001–2009 84

Table 86: Men's Health Therapeutics Market, Top Five Countries in Europe, Diagnosis Population, 2009–2016 84

Table 87: Men's Health Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2001–2009 85

Table 88: Men's Health Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2009–2016 85

Table 89: Men's Health Therapeutics Market, Japan, Revenue ($m), 2001–2009 86

Table 90: Men's Health Therapeutics Market, Japan, Revenue ($m), 2009–2016 87

Table 91: Men's Health Therapeutics Market, Japan, Annual Cost of Treatment , 2001–2009 88

Table 92: Men's Health Therapeutics Market, Japan, Annual Cost of Treatment, 2009–2016 88

Table 93: Men's Health Therapeutics Market, Japan, Usage Patterns, 2001–2009 90

Table 94: Men's Health Therapeutics Market, Japan, Usage Patterns, 2009–2016 90

Table 95: Men's Health Therapeutics Market, Japan, Diseased Population, 2001–2009 91

Table 96: Men's Health Therapeutics Market, Japan, Diseased Population, 2009–2016 91

Table 97: Men's Health Therapeutics Market, Japan, Treatment Seeking Population, 2001–2009 92

Table 98: Men's Health Therapeutics Market, Japan, Treatment Seeking Population, 2009–2016 93

Table 99: Men's Health Therapeutics Market, Japan, Diagnosis Population, 2001–2009 94

Table 100: Men's Health Therapeutics Market, Japan, Diagnosis Population, 2009–2016 94

Table 101: Men's Health Therapeutics Market, Japan, Prescription Population, 2001–2009 95

Table 102: Men's Health Therapeutics Market, Japan, Prescription Population, 2009–2016 96

Table 103: Erectile Dysfunction Therapeutics –Regulatory Filing and Phase III Clinical Pipeline, 2010 102

Table 104: Erectile Dysfunction Therapeutics –Phase II Clinical Pipeline, 2010 102

Table 105: Erectile Dysfunction Therapeutics –Phase I Clinical Pipeline, 2010 103

Table 106: Erectile Dysfunction Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 103

Table 107: Premature Ejaculation Therapeutics –Regulatory Filing and Phase III Clinical Pipeline, 2010 103

Table 108: Premature Ejaculation Therapeutics –Phase II Clinical Pipeline, 2010 104

Table 109: Premature Ejaculation Therapeutics –Phase I Clinical Pipeline, 2010 104

Table 110: Premature Ejaculation Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 104

Table 111: Male Hypogonadism Therapeutics –Regulatory Filing and Phase III Clinical Pipeline, 2010 104

Table 112: Male Hypogonadism Therapeutics –Phase II Clinical Pipeline, 2010 105

Table 113: Male Hypogonadism Therapeutics –Phase I Clinical Pipeline, 2010 105

Table 114: Male Hypogonadism Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 105

Table 115: Eli Lilly and Company – Men's Health Pipeline Products, 2010 111

Table 116: GlaxoSmithKline, Inc – Men's Health Pipeline Products, 2010 112

Table 117: Abbott Laboratories– Men's Health Pipeline Products, 2010 113

Table 118: Endo Pharmaceuticals Holding Inc. – Men's Health Pipeline Products, 2010 114

Table 119: VIVUS, Inc. – Men's Health Pipeline Products, 2010 116

Table 120: Watson Pharmaceuticals, Inc. – Men's Health Pipeline Products, 2010 120

1.2 List of Figures

Figure 1: Men's Health Therapeutics Market, Global, Drivers and Restraints, 2009 12

Figure 2: Men's Health Therapeutics Market, Global, Revenue ($m), 2001-2016 13

Figure 3: Men's Health Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2016 14

Figure 4: Men's Health Therapeutics Market, Global, Treatment Usage Patterns, 2001-2016 15

Figure 5: Men's Health Therapeutics Market, Global, Diseased Population, 2001-2016 17

Figure 6: Men's Health Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 18

Figure 7: Men's Health Therapeutics Market, Global, Diagnosis Population, 2001-2016 19

Figure 8: Men's Health Therapeutics Market, Global, Prescription Population, 2001-2016 21

Figure 9: Men's Health Therapeutic Market, Global, Market Share by Geography, 2009 and 2016 22

Figure 10: Men's Health Therapeutic Market, Global, Branded v/s Generic Drugs, 2009 23

Figure 11: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2001-2016 27

Figure 12: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 28

Figure 13: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, 2001-2016 29

Figure 14: Erectile Dysfunction Therapeutics Market, Global, Diseased Population, 2001-2016 31

Figure 15: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 32

Figure 16:Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population, 2001-2016 34

Figure 17: Erectile Dysfunction Therapeutics Market, Global, Prescription Population, 2001-2016 35

Figure 18: Erectile Dysfunction Therapeutic Market, Global, Market Share by Geography, 2009 and 2016 36

Figure 19: Male Hypogonadism Therapeutics Market, Global, Revenue ($m), 2001-2016 40

Figure 20: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 41

Figure 21: Male Hypogonadism Therapeutics Market, Global, Usage Patterns, 2001-2016 42

Figure 22: Male Hypogonadism Therapeutics Market, Global, Diseased Population, 2001-2016 44

Figure 23: Male Hypogonadism Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 45

Figure 24: Male Hypogonadism Therapeutics Market, Global, Diagnosis Population, 2001-2016 46

Figure 25: Male Hypogonadism Therapeutics Market, Global, Prescription Population, 2001-2016 48

Figure 26: Male Hypogonadism Therapeutic Market, Global, Market Share by Geography, 2009 and 2016 49

Figure 27: Premature Ejaculation Therapeutics Market, Global, Revenue ($m), 2001-2016 52

Figure 28: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 53

Figure 29: Premature Ejaculation Therapeutics Market, Global, Usage Patterns, 2001-2016 54

Figure 30: Premature Ejaculation Therapeutics Market, Global, Diseased Population, 2001-2016 56

Figure 31: Premature Ejaculation Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 57

Figure 32: Premature Ejaculation Therapeutics Market, Global, Diagnosis Population, 2001-2016 59

Figure 33: Premature Ejaculation Therapeutics Market, Global, Prescription Population, 2001-2016 60

Figure 34: Premature Ejaculation Therapeutic Market, Global, Market Share by Geography, 2009 and 2016 62

Figure 35: Men's Health Market, Global, Market Forecasts by Geography ($m), 2001–2016 64

Figure 36: Men's Health Market, Global, Geography Benchmarking, 2009 and 2016 65

Figure 37: Men's Health Therapeutics Market, The US, Revenue ($m), 2001-2016 66

Figure 38: Men's Health Therapeutics Market, The US, Annual Cost of Treatment ($), 2001-2016 68

Figure 39: Men's Health Therapeutics Market, The US, Usage Patterns, 2001-2016 69

Figure 40: Men's Health Therapeutics Market, The US, Diseased Population, 2001-2016 71

Figure 41: Men's Health Therapeutics Market, The US, Treatment Seeking Population, 2001-2016 72

Figure 42: Men's Health Therapeutics Market, The US, Diagnosis Population, 2001-2016 73

Figure 43: Men's Health Therapeutics Market, The US, Prescription Population, 2001-2016 75

Figure 44: Men's Health Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2001-2016 76

Figure 45: Men's Health Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2001-2016 78

Figure 46: Men's Health Therapeutics Market, Top Five Countries in Europe, Usage Patterns, 2001-2016 79

Figure 47: Men's Health Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2001-2016 81

Figure 48: Men's Health Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2001-2016 82

Figure 49: Men's Health Therapeutics Market, Top Five Countries in Europe, Diagnosis Population, 2001-2016 83

Figure 50: Men's Health Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2001-2016 85

Figure 51: Men's Health Therapeutics Market, Japan, Revenue ($m), 2001-2016 86

Figure 52: Men's Health Therapeutics Market, Japan, Annual Cost of Treatment, 2001-2016 87

Figure 53: Men's Health Therapeutics Market, Japan, Usage Patterns, 2001-2016 89

Figure 54: Men's Health Therapeutics Market, Japan, Diseased Population, 2001-2016 91

Figure 55: Men's Health Therapeutics Market, Japan, Treatment Seeking Population, 2001-2016 92

Figure 56: Men's Health Therapeutics Market, Japan, Diagnosis Population, 2001-2016 94

Figure 57: Men's Health Therapeutics Market, Japan, Prescription Population, 2001-2016 95

Figure 58: Men's Health Market, Global, R&D Pipeline by Indication (%), 2010 97

Figure 59: Men's Health Market, Global, R&D Pipeline by Phase (%), 2010 98

Figure 60: Men's Health Market, Global, R&D Pipeline by Phase in Erectile Dysfunction (%), 2010 99

Figure 61: Men's Health Market, Global, R&D Pipeline by Phase in Premature Ejaculation Market (%), 2010 100

Figure 62: Men's Health, Global, R&D Pipeline by Phase in Male Hypogonadism (%), 2010 101

Figure 63: Pfizer Inc., SWOT Analysis, 2010 110

Figure 64: Eli Lilly and Company, SWOT Analysis, 2010 111

Figure 65: GlaxoSmithKline, Inc, SWOT Analysis, 2010 112

Figure 66: Abbott Laboratories, SWOT Analysis, 2010 113

Figure 67: Endo Pharmaceuticals Holding Inc, SWOT Analysis, 2010 114

Figure 68: Janssen-Cilag EMEA, SWOT Analysis, 2010 115

Figure 69: VIVUS Inc., SWOT Analysis, 2010 116

Figure 70: Auxilium Pharmaceuticals, Inc, SWOT Analysis, 2010 117

Figure 71: APP Pharmaceuticals, Inc, SWOT Analysis, 2010 118

Figure 72: Columbia Laboratories, Inc., SWOT Analysis, 2010 119

Figure 73: Watson Pharmaceuticals, Inc., SWOT Analysis, 2010 120

Figure 74: Valeant Pharmaceuticals International, SWOT Analysis, 2010 121

Figure 75: Men's Health Market, Global, M&A Deals by Indication (%), 2010 122

Figure 76: Men's Health Market, Global, M&A Deals by Value, $m, (%), 2010 123

Figure 77: Men's Health Market, Global, M&A Deals by Geography, (%), 2010 124

Figure 78: Men's Health Market, Global, M&A Deals by Type, (%), 2010 125

Figure 79: Men's Health Market, Global, Major Licensing Agreements By Indication (%), 2010 128

Figure 80: Men's Health Market, Global, Major Licensing Agreements By Geography (%), 2010 129

Figure 81: GBI Research Market Forecasting Methodology, 2010 137

Companies mentioned

Pfizer Inc.

Eli Lilly and Company

GlaxoSmithKline, Inc

Abbott Laboratories (Abbott acquired Solvay Pharmaceuticals)

Endo Pharmaceuticals Holding Inc.

Janssen-Cilag EMEA

VIVUS, Inc.

Auxilium Pharmaceuticals, Inc.

APP Pharmaceuticals (acquired by Fresenius Kabi Pharmaceuticals)

Columbia Laboratories, Inc.

Watson Pharmaceutical, Inc.

Valeant Pharmaceuticals International

To order this report:

Pathology Industry:

Pathology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Reportlinker Adds Renal Cell Carcimona Drug Discoveries - what the future holds

Tue, 31 Aug 2010 14:58:33 +0000

Reportlinker Adds Renal Cell Carcimona Drug Discoveries - what the future holds

PR Newswire

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Renal Cell Carcimona Drug Discoveries - what the future holds

http://www.reportlinker.com/p0192417/Renal-Cell-Carcimona-Drug-Discoveries---what-the-future-holds.html

This is a very exciting time in the treatment of renal cell carcinoma (RCC)...

With the advent of the new targeted therapies there has been a complete shift in paradigm. Treatment options for patients with advanced disease have improved dramatically; until recently there was limited choice and therapies were poorly tolerated, with relatively low response rates. Patients now face multiple options with improved safety and efficacy, and there are plenty of further therapies in the pipeline. The overall prognosis has changed for these patients and survival is now much longer.

While the RCC market has traditionally constituted a relatively small segment of the oncology market, it has more recently attracted considerable R&D investment from big pharma, biotechnology companies and specialty pharma. Older immunotherapy regimens have now been replaced as the standard of care by the newer targeted therapies launched in recent years, namely Pfizer's Sutent (sunitinib), Bayer/Onyx' Nexavar (sorafenib), Roche's Avastin (bevacizumab) and Pfizer's Torisel (temsirolimus). Since the launch of these agents in 2005/2006, the RCC market has become a rapidly-growing segment, with almost US$2.2 billion spent on branded drugs in 2008.

Significant opportunities still exist for products to expand within this marketplace. A large percentage of patients are not currently treated with drug therapies and are not cured by surgery alone; patients with localised and locally-advanced disease represent a significant patient population that may be suitable for adjuvant therapy with targeted therapies. Established agents such as Sutent, Nexavar and Avastin are being investigated in the adjuvant setting, along with new therapies including Wilex' Rencarex (girentuximab), currently in Phase III trials. In addition, many patients do not respond to current therapies, and more effective product introductions and greater use of combination therapies will address this clinical need for patients with metastatic RCC.

This report forecasts that sales of RCC treatments will increase substantially to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%

The number of patients by value in the US, Europe (top five countries) and Japan will increase by 35.7% by 2015 (from around 613,000 in 2008 to approximately 832,000 in 2015). We estimate that approximately 18% of the RCC patient population currently receives drug therapy. By 2015, we expect a higher percentage of patients to receive treatment, reflecting an increase in the number of treatment options, improvements in drug efficacy and the use of drug therapy earlier in the course of the disease.

Why this sector is important: positive drivers

Better US diagnosis rates: Over 30% of RCC cases in the US are diagnosed at Stages III or IV, an area of high unmet clinical need.

The need for improved efficacy: Around 50% of early-stage patients are not cured by surgery and around 80% of patients with advanced disease fail to respond to approved therapies.

Alternative drug administration: Current immunotherapy requires frequent administration, intramuscularly or intravenously, and the advent of longer-acting oral products will be welcomed by clinicians and patients alike.

More therapy choice: New treatments will gain broader indications in the treatment of RCC eg in the adjuvant or neoadjuvant setting at earlier stages of disease due to their proven track record of safety and efficacy.

Improved funding: Increased accessibility to cancer drugs via Medicare reform, Medicaid coverage and the European and Japanese regulatory health authorities.

The shape of the RCC sector in 2008...

In 2008, the RCC market was driven by sales of new targeted agents, namely Pfizer's Sutent (sunitinib) and Bayer/Onyx' Nexavar (sorafenib) as the clear leaders, followed by Roche's Avastin (bevacizumab) and Pfizer's Torisel (temsirolimus). Together these therapies secured sales of almost US$1.8 billion. Just five major players competed for a share of the RCC market. The introduction of targeted therapies in 2005/2006 has seen Pfizer and Bayer/Onyx come from nowhere to now dominate with a combined 67% market share.

...and in 2015

The total RCC sales for branded products will increase substantially from almost US$2.2 billion in 2008, to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%. Sales will be driven by the new targeted therapies which will account for sales of around US$6.1 billion in 2015, with Pfizer's Sutent, Bayer/Onyx' Nexavar, Roche's Avastin and GlaxoSmithKline's Armala/Votrient responsible for approximately US$4.5 billion of this. There are four current Phase III products which have the potential to reach the market by 2015, including Wilex' Rencarex.

EXECUTIVE SUMMARY

WHAT IS RENAL CELL CARCINOMA?

Stages of the Disease

Risk Factors

PATIENT STATISTICS

Incidence and Mortality

Survival and Stage at Diagnosis

PATIENT MODEL

DRUG GROWTH DRIVERS

DRUG GROWTH RISKS/DAMPENERS

CURRENT TREATMENTS

Leading Brands

Current Products' Patent Exposure

THE CURRENT RENAL CELL CARCINOMA MARKET

PLAYERS AND PRODUCTS IN 2008

Geographic Areas

RESEARCH & DEVELOPMENT OF RCC DRUGS

WHAT THE FUTURE HOLDS

GLOBAL SALES FORECASTS TO 2015

Model Assumptions

PLAYERS AND PRODUCTS IN 2015

COMPETITOR RATIO ANALYSIS

Competitor Ratio Analysis Criteria

COMPETITOR RATIO ANALYSIS - PRODUCTS

COMPETITOR RATIO ANALYSIS - COMPANIES

Winners and Losers

Winners

Losers

Analysis of Leading Brands

Targeted Therapies

Armala/Votrient

Avastin

Afinitor

Nexavar

Oncophage

Sutent

Torisel

Immunotherapies

Intron A

Roferon-A

Pegasys

PEG-Intron

Proleukin

Analysis Of Products Under Development

Phase III Projects

Anyara

Axitinib

Rencarex

Tivozanib

Phase II Projects

Archexin

AS1411

Foretinib

IMA901

Interleukin-21

Perifosine

Regorafenib

Talactoferrin alpha

Phase I/II Projects

AGS-003

ImmuFact

DISCONTINUATION OF DRUGS

APPENDIX 1

Appendix 2

Appendix 3

Phase Transition Probability

RCC GLOSSARY

Index of Tables

RCC Stages

RCC Stage at Diagnosis, US

Five-year Relative Survival Rates by Stage at Diagnosis, 1996-2004

RCC US Population Model, 2008-2015

RCC European Population Model, 2008-2015

RCC Japanese Population Model, 2008-2015

RCC Population Models, Top Seven Countries, 2008-2015

Worldwide RCC Population Model, 2008-2015

Summary of Standard Treatment Options for RCC

Comparison of Leading RCC Agents

Comparison of Recently-Launched RCC Agents

Patent Exposure of Leading Brands

Drugs in Development to Treat RCC

Timeline of Selected RCC Development Projects

Sales Forecasts of Current and Future Leading RCC Drugs (US$ millions)

Key RCC Drugs Analysed

Summary of Key Companies in the RCC Market by 2015

Axitinib Treatment-Related Adverse Events

Drugs Discontinued from Clinical Development in RCC

Fuhrman Grading System for Renal Cell Carcinoma

TNM Staging of Renal Cell Carcinoma

AJCC Stage Groupings

Probability of Launch

Index of Charts

Schematic of Kidney

RCC Incidence by Age at Diagnosis, UK

Worldwide Incidence of the Major Cancers, 2008

International Variation in RCC Incidence Rates, 2002

RCC Incidence Rates for Selected Countries, 2002

US Kidney Cancer Incidence Rates by Age, 1992-2006

US Age-Adjusted Kidney Cancer Incidence Rates by Race/Ethnicity, 1992-2006

US Kidney Cancer Mortality Rates by Age, 1992-2006

Projected % Change in Age-Standardised RCC Mortality in the US, Europe and Japan, 2002-2015

RCC Mortality Rates for Selected Countries, 2002

RCC Incidence, Top Seven Countries, 2008-2015

RCC Mortality, Top Seven Countries, 2008-2015

Market Share (Branded Sales) of Top Five Cancers, 2008

Therapy Sales Split for Major Branded RCC Products, 2008

Market Share for Major Branded RCC Products, 2008

Market Share for Major RCC Players, 2008

Sales Forecasts of RCC Therapies Launched in 2008 (US$ millions)

Sales Forecasts of RCC Therapies Launched from 2009 (US$ millions)

Therapy Sales Split for Major Branded RCC Products, 2015

Market Share for Major Branded RCC Products, 2015

Market Share for Major RCC Players, 2015

Competitor Ratio Analysis Scores by Product

Major RCC Products, 2008

Analysis of RCC Products based on Drug Class, 2015

Table of Contents

©Espicom Business Intelligence vi February 2010

Section Name Renal Cell Carcinoma Drug Discoveries

Analysis of RCC Products based on Delivery, 2015

Competitor Ratio Analysis of RCC Products Based on Company, 2015

Votrient/Armala RCC Sales (2009E-2015E)

Avastin Mode of Action

Avastin RCC Sales (2008E-2015E)

Afinitor Mode of Action

Afinitor RCC Sales (2009E-2015E)

Nexavar's Dual Mode of Action

Nexavar RCC Sales (2008E-2015E)

Oncophage RCC Sales (2009E-2015E)

Sutent Mode of Action

Sutent RCC Sales (2008E-2015E)

Torisel's Mode of Action

Torisel RCC Sales (2008E-2015E)

Intron A RCC Sales (2008E-2015E)

Roferon-A RCC Sales (2008E-2015E)

Pegasys RCC Sales (2008E-2015E)

PEG-Intron RCC Sales (2008E-2015E)

Proleukin Mode of Action

Proleukin RCC Sales (2008E-2015E)

Anyara's Mode of Action

Anyara RCC Sales (2013E-2015E)

Axitinib RCC Sales (2012E-2015E)

Rencarex' Mode of Action

Tivozanib RCC Sales (2013E-2015E)

Signalling Pathways Affected by Archexin

AS1411 Proposed Mechanism of Action

Mode of Action of IMA901

IL-21 Initiating Antibody-mediated Tumour Lysis

Perifosine's Mechanism of Action

Talactoferrin's Mechanism of Action in Cancer.

To order this report:

Drug Discovery and Development Industry: Renal Cell Carcimona Drug Discoveries - what the future holds

Drug Discovery and Development Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market

Tue, 31 Aug 2010 13:45:00 +0000

An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market

The COPD Drug Market Will Reach More Than $13 Billion in 2019, According to Findings from Decision Resources

PR Newswire

BURLINGTON, Mass., Aug. 31 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.

The Pharmacor 2010 findings from the topic entitled Chronic Obstructive Pulmonary Disease reveal that the COPD drug market, which totaled nearly $8.4 billion in 2009, will reach more than $13 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The findings also reveal that the drug-treated COPD population will increase by nearly 6 million patients over the next decade. Although two maintenance therapies currently dominate the COPD market—GlaxoSmithKline's Advair/Seretide/Adoair and Boehringer Ingelheim/Pfizer's Spiriva—the near-term market will become fractured owing to the launch of new agents and generic erosion of key brands.

The Pharmacor 2010 findings also reveal that the makers of lower-priced branded generics will capitalize on the loss of market exclusivity of Advair/Seretide/Adoair and Spiriva in the United States and Europe, and generic versions of these drugs will become available in Europe by 2019.

"Challenging regulatory environments, uncertain pricing and reimbursement restrictions and the loss of patent protection and/or market exclusivity for many top-selling COPD products will constrain the COPD market," said Decision Resources Analyst Benjamin Guikema, Ph.D. "However, manufacturers of generic products will face great barriers to entering the COPD market, given the lack of clear regulatory pathways and the difficulty of creating a device that is acceptable to regulators, physicians and patients."

The findings also reveal that the launch of fixed-dose combination inhalers containing a long-acting beta2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA) will offer more potent bronchodilation than currently available treatments.

"Thought leaders hope that LABA/LAMA combinations will also be more effective than currently available treatments in reducing the frequency of COPD exacerbations," Dr. Guikema said.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:

Decision Resources, Inc.
Christopher Comfort
781-296-2597
ccomfort@dresources.com

SOURCE Decision Resources

GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine

Tue, 31 Aug 2010 00:22:44 +0000

GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine

PR Newswire

LONDON, RESEARCH TRIANGLE PARK, N.C., and ALISO VIEJO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine* to 30 November 2010. The original goal date was 30 August 2010.

The FDA has not yet completed the review of the New Drug Application (NDA) for ezogabine due to the recent submission of a formal REMS (Risk Evaluation and Mitigation Strategy) for ezogabine, an investigational anti-epileptic drug being studied for the adjunctive treatment of adults with partial onset seizures. The REMS was requested by FDA in correspondence dated 16 August 2010 and submitted to the FDA on 26 August 2010.

The NDA was submitted to the FDA on 30 October 2009. The companies will continue to work closely with FDA as the Agency completes its review.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

Valeant Pharmaceuticals – Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

GlaxoSmithKline cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.

Valeant Pharmaceuticals Forward-Looking Statement

This press release may contain forward-looking statements, including, but not limited to, statements regarding the review by the FDA with respect to, and the timing of, any marketing approval for ezogabine. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC"). Forward-looking information contained in this press release does not take into account or give effect to the impact of the proposed merger with Biovail. Additional uncertainties relating to the proposed merger with Biovail are discussed under the heading "Risk Factors" in the definitive joint proxy statement/prospectus contained in the Schedule 14A filed by Valeant on August 23, 2010 with the SEC. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

*Editor's note: Ezogabine is the non-proprietary name adopted by the United States Adopted Name Council for use in the U.S. and Canada. Retigabine is the non-proprietary name adopted by the International Nonproprietary Name for Pharmaceuticals Substances Program for use in the rest of the world.

SOURCE GlaxoSmithKline

GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine

Tue, 31 Aug 2010 00:15:00 +0000

GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine

PR Newswire

LONDON, RESEARCH TRIANGLE PARK, N.C. and ALISO VIEJO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine* to 30 November 2010. The original goal date was 30 August 2010.

(Logo: http://photos.prnewswire.com/prnh/20081125/VALEANTLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

The NDA was submitted to the FDA on 30 October 2009. The companies will continue to work closely with FDA as the Agency completes its review.


GlaxoSmithKline Enquiries:
UK Media enquiries:	David Mawdsley	(020) 8047 5502
	Claire Brough	(020) 8047 5502
	Stephen Rea	(020) 8047 5502
	Alexandra Harrison	(020) 8047 5502
	Jo Revill	(020) 8047 5502

US Media enquiries:	Nancy Pekarek	(919) 483 2839
	Mary Anne Rhyne	(919) 483 2839
	Kevin Colgan	(919) 483 2839
	Sarah Alspach	(919) 483 2839

European Analyst/Investor enquiries:	Sally Ferguson	(020) 8047 5543
	Gary Davies	(020) 8047 5503

US Analyst/ Investor enquiries:	Tom Curry	(215) 751 5419
	Jen Hill Baxter	(215) 751 7002
Valeant Inquiries:	Laurie W. Little	(949) 461 6002

GlaxoSmithKline cautionary statement regarding forward-looking statements

Valeant Pharmaceuticals Forward-Looking Statement


Registered in England & Wales: No. 3888792

Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS

SOURCE Valeant Pharmaceuticals International

Virgin America and SU2C Join Forces to Stand Up To Cancer at 35,000 Feet

Thu, 26 Aug 2010 13:00:00 +0000

Virgin America and SU2C Join Forces to Stand Up To Cancer at 35,000 Feet

Virgin America Named Official Domestic Airline of the Stand Up To Cancer Initiative

Airline Launches In-flight Digital Fundraising Drive with 100% of Funds Going to Accelerate Cancer Research

PR Newswire

LOS ANGELES and SAN FRANCISCO, Aug. 26 /PRNewswire/ -- Stand Up To Cancer (SU2C) and Virgin America, the California-based airline that is reinventing travel, today announce a unique partnership to raise awareness and funds for cancer research. As SU2C's Official Domestic Airline partner, Virgin America (with Virgin Unite) has pledged to support SU2C's mission through a multi-year in-kind travel partnership, Company fundraising and other joint efforts to drive awareness and funding for lifesaving cancer research. As of September 3, 2010, guests on Virgin America will be able to join the SU2C movement at 35,000 feet via the Red™ entertainment platform. Virgin America flight guests can visit the Shop "Make a Difference" section on the Red platform, choose a donation, swipe a credit card and join the fight to bring an end to cancer – right from their seatback touch-screen. 100% of the funds will go to cancer research and efforts designed to speed groundbreaking treatments to patients.

(Logo: http://photos.prnewswire.com/prnh/20090123/VIRGINAMERICALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090123/VIRGINAMERICALOGO)

"Virgin America and Virgin Unite are delighted to join forces with Stand Up To Cancer to raise critical funding for cancer research. In addition to the commitment we've made, we hope that millions of travelers will join the fight – from the comfort of their seats at 35,000 feet," said Virgin Group Founder Sir Richard Branson.

The Virgin America-SU2C partnership kicks off just as SU2C returns to primetime television on September 10, 2010, at 8:00PM ET & PT / 7:00PM CT. The star-studded show combines entertainment with an appeal to build continuing public support for cutting-edge cancer research that translates from the laboratory to treatments and technologies that benefit patients. Guests traveling on Virgin America on September 10, 2010, will be able to tune into the show live via the airline's live satellite television line-up. In addition to the unique donation platform on the Red in-flight entertainment system, Virgin America flyers will also be able to watch custom SU2C content on the Red platform throughout the rest of 2010 and in 2011.

"Ending cancer is going to require a true grassroots effort," said Laura Ziskin, one of the Stand Up To Cancer co-founders. "We need for people all over the country to believe that curing cancer is do-able, and to give whatever they can to help the teams of scientists working 24/7 to make that happen. This type of support from a major airline, where guests can learn about our researchers' work and easily donate, is a first for us. We are profoundly grateful to Richard Branson and everyone at Virgin America for standing up to cancer with us," she said.

With Virgin Unite, the nonprofit foundation of the Virgin Group, Virgin America teammates are joining the fight as well. In September 2010, Virgin America in-flight and airport teammates will be wearing SU2C tee shirts on select days and competing to drive donations among their network of friends and family via the Virgin America team page on SU2C's Web site. In addition to the multi-year in-kind travel partnership, Virgin America will be matching the initial teammate fundraising drive up to $10,000. Virgin America's top teammate fundraiser as of September 6, 2010, will score a VIP seat at the live taping of the 2010 SU2C televised event.

"Cancer has touched all of us in some way and has deeply affected the Virgin America family. Our Company and our teammates are pleased to have the opportunity to help raise funds for the multidisciplinary research that is changing the equation and helping speed lifesaving treatments to patients," said Frances Fiorillo, Senior Vice President of People and In-Flight Services at Virgin America.

ABC, CBS, FOX, NBC and many cable networks are donating one hour of simultaneous commercial-free primetime for this year's SU2C nationally televised fundraising special. Similar to the landmark 2008 broadcast, this year's telecast will feature legendary recording artists and stars from film, television and sports who will present content providing viewers with insights into cancer. This year's show will also include a special appearance by a Virgin America aircraft. While the broadcast will honor the memory of those taken by the disease, it will focus on surviving cancer – on living a full life after being diagnosed with it. In the United States alone this year, 1.4 million people will be diagnosed with cancer.

Virgin America offers over 100 flights a day and flies to: San Francisco, Los Angeles, New York, Washington D.C., Seattle, Las Vegas, San Diego, Boston, Fort Lauderdale, Toronto, Orlando (starting October 6, 2010) and Dallas-Fort Worth (starting December 1, 2010).

EDITORS NOTE: Virgin America is a U.S.-controlled and operated airline and is an entirely separate company from Virgin Atlantic. Sir Richard Branson's Virgin Group is a minority share investor in Virgin America.

About Virgin America: Headquartered in California and launched in August 2007, Virgin America is one of the fastest growing new U.S. airlines of all time and currently employs over 1600 people. Virgin America offers guests attractive fares and a host of innovative features aimed at reinventing air travel. The airline's base of operations is San Francisco International Airport's International Terminal. The airline's new aircraft offer interactive in-flight entertainment systems and power outlets near every seat for electronic gear. Virgin America offers in-flight internet service on every flight and hosts the largest in-flight entertainment library in the North American skies via the touch-screen Red™ seatback platform. In addition to a 30-film library including Oscar winners, foreign language films and Hollywood blockbusters, Red features live TV, videogames, seat-to-seat chat, 3,000 MP3s, music videos, interactive Google maps and more. In just three years flying, Virgin America was named "Best Domestic Airline in the Conde Nast Traveler 2008 and 2009 Readers' Choice Awards and "Best Domestic Airline" in Travel + Leisure's 2008, 2009 and 2010 World's Best Awards. For more: www.virginamerica.com

About the Stand Up To Cancer Initiative: Stand Up To Cancer (SU2C) -- a program of the Entertainment Industry Foundation (EIF), a 501(c)3 charitable organization -- raises funds to hasten the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. In the fall of 2007, a group of women whose lives have all been affected by cancer in profound ways began working together to marshal the resources of the media and entertainment industries in the fight against this disease. The SU2C founding members include Laura Ziskin, executive producer of the Sept. 5, 2008 broadcast and the upcoming one, who is a cancer survivor; Sherry Lansing, chairperson of the Entertainment Industry Foundation's Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; Katie Couric; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; nonprofit executive Ellen Ziffren; and Noreen Fraser, founder of the Noreen Fraser Foundation (NFF) and a cancer survivor. SU2C was formally launched on May 27, 2008. Major League Baseball was the founding donor to contribute to Stand Up To Cancer. Other major SU2C supporters include Sidney Kimmel, the country's largest individual supporter of cancer research; Amgen, Bloomberg Philanthropies, Cancer Treatment Centers of America, The Gateway for Cancer Research Foundation, GlaxoSmithKline, Inter-American Development Bank (IDB), Wallis Annenberg & The Annenberg Foundation, Alliance for Global Good, Milken Family Foundation, Philips Electronics, Steve Tisch, The Island Def Jam Music Group, and many others. In addition to ABC, CBS, FOX and NBC, SU2C major media partners include AOL, Conde Nast Media Group, eBay Inc., Facebook, Hachette Filipacchi Media U.S., Hearst Corporation, Los Angeles Times, Meredith Corporation, The New York Times Company, Time Inc and WebMD. For more: www.standup2cancer.org.

SOURCE Virgin America

Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market

Wed, 25 Aug 2010 13:00:00 +0000

Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market

Dainippon Sumitomo Pharma/Sepracor's Lurasidone Will Become a Market Leader in 2019, According to Findings from Decision Resources

PR Newswire

WALTHAM, Mass., Aug. 25 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's Depakote/Abbott's Depakote ER, generics), combined with projected generic erosion of the atypical antipsychotic drug class will cause a precipitous $2.3 billion decline in the bipolar disorder drug market over the next decade.

The Pharmacor 2010 findings from the topic entitled Bipolar Disorder reveal that although patient share for atypical antipsychotics will increase through 2019, particularly in France, Germany, Italy, Spain, the United Kingdom and Japan, sales of atypical antipsychotics will decline significantly over the forecast period owing to the generic erosion of key agents such as AstraZeneca/Astellas's Seroquel/AstraZeneca's Seroquel XR, Eli Lilly's Zyprexa, Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and Pfizer's Geodon.

The Pharmacor 2010 findings reveal that bipolar depression is the largest unmet need in bipolar disorder, as experts consistently indicate that few therapies achieve sufficient efficacy in this market segment. Two emerging atypical antipsychotics will likely gain approval for bipolar depression: Forest Laboratories/Gedeon Richter/Mitsubishi Pharma's cariprazine and Dainippon Sumitomo Pharma/Sepracor's (soon to be Sunovion Pharmaceuticals) lurasidone. Lurasidone, which is expected to gain approval for bipolar depression in 2012, will become a market leader in 2019.

"The bipolar depression market segment represents the greatest commercial opportunity and we expect that lurasidone will gain approval for bipolar depression in 2012, following its launch in 2011 for the treatment of schizophrenia," said Decision Resources Analyst Alana Simorellis, Ph.D. "Dainippon Sumitomo Pharma and Sepracor will differentiate lurasidone based on its efficacy in bipolar depression, as well as its potential for efficacy in cognitive symptoms, and its relatively mild weight gain profile compared with currently marketed atypical antipsychotics. As a result, we forecast lurasidone to garner peak year sales in the range of $500 million to $1 billion."

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

About Decision Resources, Inc.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

CONTACT:

Decision Resources, Inc.

Lisa Osgood

+1-781-296-2606

losgood@hl-isy.com

SOURCE Decision Resources

Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Wed, 25 Aug 2010 12:15:53 +0000

Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?

PR Newswire

NEW YORK, Aug. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Protein Kinase Therapeutics in Oncology - Where to Commercialize?

http://www.reportlinker.com/p0284973/Protein-Kinase-Therapeutics-in-Oncology---Where-to-Commercialize.html

This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3

2 About Cancer Highlights 4

3 Methodologies 6

4 Table of Contents 8

4.1 List of Figures 19

4.2 List of Tables 19

5 Introduction 30

5.1 The Scope of this Report 30

5.2 Definitions 35

5.3 Abbreviations 35

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 36

6.1 Drug Repositioning in Oncology 36

6.2 Introduction to Protein Kinase Therapeutic Targets in Oncology 37

6.2.1 Carboxy-lyase Activity Targets 39

6.2.2 Catalytic Activity Targets 40

6.2.3 Cell Adhesion Molecule Activity Targets 43

6.2.4 Chaperone Activity Targets 45

6.2.5 Cysteine-Type Peptidase Activity Targets 47

6.2.6 DNA Topoisomerase Activity Targets 49

6.2.7 G-Protein Coupled Receptor Activity Targets 51

6.2.8 Growth Factor Activity Targets 52

6.2.9 Hydrolase Activity Targets 57

6.2.10 Kinase Activity Targets 58

6.2.11 Kinase Regulator Activity Targets 68

6.2.12 Lipid Kinase Activity Targets 72

6.2.13 Lipid Phosphatase Activity Targets 79

6.2.14 Oxidoreductase Activity Targets 80

6.2.15 Peroxidase Activity Targets 81

6.2.16 Protein Binding Targets 82

6.2.17 Protein Serine/Threonine Kinase Activity Targets 84

6.2.18 Protein Threonine/Tyrosine Kinase Activity Targets 144

6.2.19 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 147

6.2.20 Protein-Tyrosine Kinase Activity Targets 148

6.2.21 Protein-Tyrosine Kinase Activity Targets 150

6.2.22 Receptor Activity Targets 174

6.2.23 Receptor Binding Targets 176

6.2.24 Receptor Signaling Complex Scaffold Activity Targets 177

6.2.25 Structural Constituent of Cytoskeleton Targets 178

6.2.26 Transcription Factor Activity Targets 179

6.2.27 Transcription Regulator Activity Targets 192

6.2.28 Translation Regulator Activity Targets 193

6.2.29 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 194

6.2.30 Transporter Activity Targets 254

6.3 The Cancer Genome Project and Protein Kinase Therapeutic Targets in Oncology 258

6.3.1 Protein Kinase Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 258

6.4 Structure-based Drug Design in Protein Kinase Therapeutics is Stimulated by Available Structure Data on Biological Targets 262

6.5 Target-Target Interactions among Identified Protein Kinase Therapeutics Targets in Oncology 265

6.6 The Drug-Target Interactome 270

6.7 Protein Expression Levels of Identified Protein Kinase Therapeutic Targets in Oncology 275

6.8 Pathway Analysis of Cancer Protein Kinase Therapeutic Targets 279

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? 337

7.1 Terminated Drug Target Profiles of Cancer Protein Kinase Drugs 340

7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 345

7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 347

7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 350

7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 356

7.6 Preclinical Development: New and Unique Drug Target Profiles of Protein Kinase Therapeutics in Oncology 364

7.7 Development Profiles of All Protein Kinase Drugs in Oncology 374

8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type 408

8.1 Small Molecules 410

8.1.1 Background 410

8.1.2 Target Profiles of Small Molecular Drugs 411

8.2 Peptide/Protein Drugs 460

8.2.1 Background 460

8.2.2 Target Profiles of Peptide and Protein Drugs 461

8.3 Antibodies and Antibody-like Structures 465

8.3.1 Background 465

8.3.2 Target Profiles of Antibody Drugs 465

8.4 Nucleic Acid Therapies 469

8.4.1 Background 469

8.4.2 Target Profiles of Nucleic Acid Drugs 470

8.5 Cell and Gene Therapy 472

8.5.1 Background 472

8.5.2 Target Profiles of Cell- and Gene Therapy Drugs 473

8.6 The Competition Through Close Mechanistic Approximation of Cancer Protein Kinase Therapeutics 475

8.7 Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology 489

9 Selecting Cancer Indications for Protein Kinase Therapeutics 496

9.1 Acute Lymphocytic Leukemia 499

9.2 Acute Myelogenous Leukemia 501

9.3 Adrenal Cancer 505

9.4 B-cell Lymphoma 506

9.5 Basal Cell Cancer 508

9.6 Benign prostatic hyperplasia 508

9.7 Biliary Cancer 509

9.8 Bladder Cancer 510

9.9 Bone Cancer 512

9.10 Brain Cancer 513

9.11 Breast Cancer 517

9.12 Carcinoid 525

9.13 Cervical Cancer 526

9.14 Chronic Lymphocytic Leukemia 528

9.15 Chronic Myelogenous Leukemia 530

9.16 Colorectal Cancer 533

9.17 Endometrial Cancer 541

9.18 Fallopian Tube Cancer 543

9.19 Gastrointestinal Cancer (general) 545

9.20 Gastrointestinal Stomach Cancer 547

9.21 Gastrointestinal Stromal Cancer 549

9.22 Head and Neck Cancer 551

9.23 Hodgkin's Lymphoma 554

9.24 Leiomyo Sarcoma 555

9.25 Leukemia (general) 556

9.26 Lipo Sarcoma 558

9.27 Liver Cancer 559

9.28 Lung Cancer (general) 562

9.29 Lymphoma (general) 564

9.30 Mast Cell Leukemia 565

9.31 Melanoma 566

9.32 Mesothelioma 570

9.33 Myelodysplastic Syndrome 573

9.34 Myeloma 575

9.35 Nasopharyngeal Cancer 578

9.36 Neuroblastoma Cancer 579

9.37 non-Hodgkin's Lymphoma 580

9.38 Non-Small Cell Lung Cancer 582

9.39 Oesophageal Cancer 589

9.40 Oral Cancer 592

9.41 Osteo Sarcoma 592

9.42 Ovarian Cancer 593

9.43 Pancreatic Cancer 598

9.44 Peritoneal Cancer 602

9.45 Prostate Cancer 604

9.46 Renal Cancer 609

9.47 Rhabdomyo Sarcoma 615

9.48 Sarcoma (general) 616

9.49 Small Cell Lung Cancer 619

9.50 Soft Tissue Sarcoma 621

9.51 Squamous Cell Cancer 622

9.52 Synovial Sarcoma 623

9.53 T-cell Lymphoma 624

9.54 Testicular Cancer 625

9.55 Thymoma Cancer 626

9.56 Thyroid Cancer 627

9.57 Unspecified Cancer Indication 630

10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator 650

10.1 4SC 654

10.2 AB Science 658

10.3 Abbott 662

10.4 Abiogen 670

10.5 Abraxis BioScience 674

10.6 Advenchen 679

10.7 AEgera 682

10.8 Aeterna Zentaris 686

10.9 Aida Pharmaceuticals 693

10.10 Alethia Biotherapeutics 696

10.11 Alfacell 699

10.12 AlphaVax 702

10.13 Ambit Biosciences 706

10.14 Amgen 713

10.15 Amphora 723

10.16 Apthera 732

10.17 Ariad 736

10.18 Arno Therapeutics 744

10.19 ArQule 747

10.20 Array BioPharma 752

10.21 Astellas 757

10.22 Astex Therapeutics 760

10.23 AstraZeneca 769

10.24 Avalon 784

10.25 Bayer 787

10.26 Benitec 794

10.27 Berkeley Lab 798

10.28 BioAxone 801

10.29 Biotecnol 804

10.30 Biotica Technology 808

10.31 Boehringer Ingelheim 812

10.32 Bristol-Myers Squibb 820

10.33 BTG 837

10.34 Calistoga Pharmaceuticals 840

10.35 Callisto Pharmaceuticals 843

10.36 Cambrex 846

10.37 CanBas 849

10.38 Cancer Research Technology 852

10.39 Catalyst Biosciences 857

10.40 Celgene 861

10.41 Cell Therapeutics 864

10.42 Cephalon 867

10.43 Chroma Therapeutics 874

10.44 CompleGen 878

10.45 Compugen 883

10.46 CoNCERT Pharmaceuticals 887

10.47 Curis 891

10.48 Cyclacel 895

10.49 Cylene Pharmaceuticals 900

10.50 Cytokine PharmaSciences 903

10.51 Cytopia 907

10.52 Dainippon Sumitomo Pharma 911

10.53 Deciphera Pharmaceuticals 914

10.54 DeveloGen 923

10.55 Dyax 927

10.56 Eisai 930

10.57 Elara Pharmaceuticals 937

10.58 Eli Lilly 940

10.59 Enkam Pharmaceuticals 948

10.60 EntreMed 952

10.61 Exelixis 955

10.62 Galapagos 970

10.63 Genentech 973

10.64 Generex 977

10.65 GlaxoSmithKline 981

10.66 GlycoGenesys 991

10.67 GPC Biotech 995

10.68 Hanmi 998

10.69 Hoffmann-La Roche 1003

10.70 Hutchison China MediTech 1011

10.71 Idera Pharmaceuticals 1014

10.72 ImClone Systems 1017

10.73 ImmunoFrontier 1023

10.74 Incyte Corporation 1027

10.75 Inhibiton Therapeutics 1030

10.76 Inovio 1033

10.77 Insmed 1036

10.78 InterMune 1039

10.79 ISU ABXIS 1042

10.80 Johnson & Johnson 1046

10.81 KAI Pharmaceuticals 1051

10.82 Kalypsys 1054

10.83 Keryx Biopharmaceuticals 1057

10.84 Kiadis 1061

10.85 Kirin Pharma 1066

10.86 KuDOS 1071

10.87 Kyowa Hakko Kirin 1074

10.88 Lexicon Pharmaceuticals 1081

10.89 Locus Pharmaceuticals 1084

10.90 Lorus Therapeutics 1087

10.91 MaxoCore Pharmaceuticals 1090

10.92 Medisyn Technologies 1093

10.93 Merck & Co 1096

10.94 MethylGene 1101

10.95 Mitsubishi Tanabe Pharma 1104

10.96 Molecular LogiX 1108

10.97 NeoPharm 1112

10.98 Nerviano Medical Sciences 1116

10.99 NicOx 1120

10.100 Nidus Laboratories 1123

10.101 NIH - The US National Institute of Health 1127

10.102 Nippon Shinyaku 1130

10.103 Non-industrial Source 1134

10.104 Novartis 1137

10.105 Novogen 1154

10.106 Oncalis 1158

10.107 Onconova 1162

10.108 OncoTherapy Science 1170

10.109 Oncothyreon 1174

10.110 OSI Pharmaceuticals 1180

10.111 Pathway Therapeutics 1192

10.112 Peregrine Pharmaceuticals 1195

10.113 Pfizer 1199

10.114 Pharmacyclics 1218

10.115 PharmaGap 1222

10.116 PharmaMar 1226

10.117 Pharmexa 1231

10.118 Phytomedics 1237

10.119 Piramal 1240

10.120 PIramed 1243

10.121 Plexxikon 1247

10.122 Provid 1250

10.123 QLT 1253

10.124 Quantum Pharmaceuticals 1257

10.125 Ras Therapeutics 1261

10.126 Reata Pharmaceuticals 1264

10.127 Receptor BioLogix 1268

10.128 Rexahn 1271

10.129 Rigel 1276

10.130 Sanofi-Aventis 1281

10.131 Sareum 1285

10.132 SBIO 1291

10.133 Scancell 1298

10.134 Schering-Plough 1301

10.135 Semafore Pharmaceuticals 1306

10.136 Sentinel Oncology 1313

10.137 SGX Pharmaceuticals 1316

10.138 Silence Therapeutics 1321

10.139 Sirna Therapeutics 1325

10.140 Sunesis 1328

10.141 SuperGen 1332

10.142 Supratek Pharma 1339

10.143 Switch Pharma 1342

10.144 Takeda 1346

10.145 Targa Therapeutics 1350

10.146 TargeGen 1355

10.147 Tekmira Pharmaceuticals 1358

10.148 Telik 1361

10.149 Thallion Pharmaceuticals 1366

10.150 Theryte 1369

10.151 ToolGen 1372

10.152 TopoTarget 1375

10.153 UCB 1380

10.154 VasGene Therapeutics 1384

10.155 Velacor Therapeutics 1387

10.156 Vertex Pharmaceuticals 1390

10.157 ViroMed 1394

10.158 Wyeth 1398

10.159 Xcovery 1410

10.160 Xencor 1414

11 Disclaimer 1418

12 Drug Index 1419

13 Company Index 1433

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Protein Kinase Drug Targets in Oncology 269

Figure 2: The Drug-Protein Interactome of Protein Kinase Drugs –Clusters I 272

Figure 3: The Drug-Protein Interactome of Protein Kinase Drugs – Clusters II 273

Figure 4: Head-to-Head Targeting Interactome of Protein Kinase Drugs 274

Figure 5: Distribution of Compound Types among Protein Kinase Drugs in Oncology 489

Figure 6: Primary Sub-cellular Localization of Drug Targets 490

4.2 List of Tables

Table 1: Competitive Pressure Force among Protein Kinase Drugs in Oncology 29

Table 2: Overall Breakdown of the Included Protein Kinase Pipeline by Cancer Indication and Stage of Development 29

Table 3: Overview of Drug Target Profile Themes 36

Table 4: Terminally Ceased Therapeutic Protein Kinase Targets in Oncology 37

Table 5: Drug Targets of Protein Kinase Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 258

Table 6: Identity of Protein Kinase Drug Targets with Available Biological Structures 261

Table 7: Number of Target-Target Interactions among Protein Kinase Drug Targets in Oncology 264

Table 8: Drug-Protein Interactome Clusters 269

Table 9: Protein Kinase Drug Targets with Available Protein Expression Profiles 274

Table 10: Pathway Summary 278

Table 11: Drug Targets without any Identified Assigned Pathways 278

Table 12: Pathway Profiles According to BioCarta of Protein Kinase Drug Targets in Oncology 279

Table 13: Pathway Profiles According to KEGG of Protein Kinase Drug Targets in Oncology 299

Table 14: Pathway Profiles According to NetPath of Protein Kinase Drug Targets in Oncology 331

Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 336

Table 16: Top Competitive Protein Kinase Target Profiles in Oncology 337

Table 17: Terminated Drug Target Strategies of Protein Kinase Drugs in Oncology 339

Table 18 New and Unique Protein Kinase Target Strategies in Cancer Currently in Pre-Registration to Marketed 344

Table 19: The Competition Through Close Mechanistic Approximation Between Marketed Protein Kinase Drugs in Oncology 345

Table 20: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase III Clinical Development 346

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Protein Kinase Drugs in Oncology 347

Table 22: New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase II Clinical Development 349

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Protein Kinase Drugs in Oncology 352

Table 24 New and Unique Protein Kinase Target Strategies in Cancer Currently in Phase I Clinical Development 355

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Protein Kinase Drugs in Oncology 360

Table 26: New and Unique Protein Kinase Target Strategies in Oncology Currently in Preclinical Development 363

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Protein Kinase Drugs in Oncology 368

Table 28: The Progression, Maturity and Competitive Comparison of Protein Kinase Drug Target Profiles in Cancer Drug Development 373

Table 29: Overview of Compound Strategy Competition Among Protein Kinase Drugs in Oncology 408

Table 30: Overview of the Competitive Landscape of Small Molecular Protein Kinase Drugs in Oncology 410

Table 31: Head-to-Head Target Competition Between Small Molecule Protein Kinase Drugs for the Treatment of Cancer 411

Table 32: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs of Protein Kinase Therapeutics in Oncology 416

Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Protein Kinase Drugs in Development 429

Table 34: Overview of the Competitive Landscape of Peptide Based Protein Kinase Drugs in Oncology 460

Table 35: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Protein Kinase Drugs in Development 460

Table 36: Overview of the Competitive Landscape of Protein Based Protein Kinase Drugs in Oncology 462

Table 37: The Competition Through Close Mechanistic Approximation Between Protein Based Protein Kinase Drugs in Oncology 462

Table 38: The Progression, Maturity and Competitive Comparison of Protein Based Protein Kinase Drugs in Development 463

Table 39: Overview of the Competitive Landscape of Antibody Protein Kinase Drugs in Oncology 464

Table 40: The Competition Through Close Mechanistic Approximation Between Antibody Protein Kinase Drugs in Oncology 465

Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Protein Kinase Drugs in Development 466

Table 42: Overview of the Competitive Landscape of Nucleic Acid Therapy Protein Kinase Drugs in Oncology 469

Table 43: The Competition Through Close Mechanistic Approximation Between Nucleic Acid Therapy Protein Kinase Drugs in Oncology 469

Table 44: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Protein Kinase Drugs in Development 470

Table 45: Potential Forms of Cell Therapy 471

Table 46: Vectors in Gene Therapy 472

Table 47: The Progression, Maturity and Competitive Comparison of Target Profiles of Cell Therapy Based Protein Kinase Drugs in Development 472

Table 48: Overview of the Competitive Landscape of Gene Therapy Protein Kinase Drugs in Oncology 472

Table 49: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Based Protein Kinase Drugs in Development 473

Table 50: The Competition Through Close Mechanistic Approximation Among All Protein Kinase Drugs in Oncology 474

Table 51: Compound Strategies based on Sub-Cellular Localization of Protein Kinase Drug Targets in Oncology 489

Table 52: Competitive Summary of Protein Kinase Drugs by Cancer Indication 495

Table 53: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Lymphocytic Leukemia 498

Table 54: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 499

Table 55: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Acute Myelogenous Leukemia 500

Table 56: The Competition through Close Mechanistic Approximation between Acute Myelogenous Drugs 502

Table 57: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Adrenal Cancer 504

Table 58: Drug Target Profiles of Protein Kinase Drugs for the Treatment of B-cell Lymphoma 505

Table 59: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 506

Table 60: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Basal Cell Cancer 507

Table 61: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Benign Prostatic Hyperplasia 507

Table 62: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Biliary Cancer 508

Table 63: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bladder Cancer 509

Table 64: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 510

Table 65: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Bone Cancer 511

Table 66: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Brain Cancer 512

Table 67: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 514

Table 68: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Breast Cancer 516

Table 69: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 521

Table 70: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Carcinoid 524

Table 71: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Cervical Cancer 525

Table 72: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 526

Table 73: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Lymphocytic Leukemia 527

Table 74: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 528

Table 75: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelogenous Leukemia 529

Table 76: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 531

Table 77: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Colorectal Cancer 532

Table 78: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 538

Table 79: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Endometrial Cancer 540

Table 80: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Fallopian Tube Cancer 542

Table 81: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 543

Table 82: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Cancer (general) 544

Table 83: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 545

Table 84: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stomach Cancer 546

Table 85: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 547

Table 86: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stromal Cancer 548

Table 87: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 549

Table 88: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Head and Neck Cancer 550

Table 89: The Competition through Close Mechanistic Approximation between Head and Neck and Cancer Drugs 552

Table 90: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Hodgkin's Lymphoma 553

Table 91: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leiomyo Sarcoma 554

Table 92: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Leukemia (general) 555

Table 93: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lipo Sarcoma 557

Table 94: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Liver Cancer 558

Table 95: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 560

Table 96: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lung Cancer (general) 561

Table 97: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 562

Table 98: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Lymphoma (general) 563

Table 99: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs 564

Table 100: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mast Cell Leukemia 564

Table 101: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Melanoma 565

Table 102: The Competition through Close Mechanistic Approximation between Melanoma Cancer Drugs 567

Table 103: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Mesothelioma 569

Table 104: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 571

Table 105: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myelodysplastic Syndrome 572

Table 106: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 573

Table 107: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Myeloma 574

Table 108: The Competition through Close Mechanistic Approximation between Myeloma Drugs 576

Table 109: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Nasopharyngeal Cancer 577

Table 110: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Neuroblastoma Cancer 578

Table 111: Drug Target Profiles of Protein Kinase Drugs for the Treatment of non-Hodgkin's Lymphoma 579

Table 112: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 580

Table 113: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Non-Small Cell Lung Cancer 581

Table 114: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drug 585

Table 115: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oesophageal Cancer 588

Table 116: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 590

Table 117: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Oral Cancer 591

Table 118: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Osteo Sarcoma 591

Table 119: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Ovarian Cancer 592

Table 120: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 595

Table 121: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Pancreatic Cancer 597

Table 122: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 600

Table 123: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Peritoneal Cancer 601

Table 124: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 602

Table 125: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Prostate Cancer 603

Table 126: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 606

Table 127: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Renal Cancer 608

Table 128: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 611

Table 129: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Rhabdomyo Sarcoma 614

Table 130: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Sarcoma (general) 615

Table 131: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 617

Table 132: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Small Cell Lung Cancer 618

Table 133: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 619

Table 134: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Soft Tissue Sarcoma 620

Table 135: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Squamous Cell Cancer 621

Table 136: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Synovial Sarcoma 622

Table 137: Drug Target Profiles of Protein Kinase Drugs for the Treatment of T-cell Lymphoma 623

Table 138: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Testicular Cancer 624

Table 139: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thymoma Cancer 625

Table 140: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Thyroid Cancer 626

Table 141: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 628

Table 142: Drug Target Profiles of Protein Kinase Drugs for the Treatment of Unspecified Cancer Indication 629

Table 143: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 640

Table 144: 4SC's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 653

Table 145: AB Science's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 657

Table 146: Abbott's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 661

Table 147: Abiogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 669

Table 148: Abraxis BioScience's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 673

Table 149: Advenchen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 678

Table 150: AEgera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 681

Table 151: Aeterna Zentaris' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 685

Table 152: Aida Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 692

Table 153: Alethia Biotherapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 695

Table 154: Alfacell's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 698

Table 155: AlphaVax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 701

Table 156: Ambit Biosciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 705

Table 157: Amgen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 712

Table 158: Amphora's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 722

Table 159: Apthera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 731

Table 160: Ariad's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 735

Table 161: Arno Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 743

Table 162: ArQule's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 746

Table 163: Array BioPharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 751

Table 164: Astellas' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 756

Table 165: Astex Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 759

Table 166: AstraZeneca's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 768

Table 167: Avalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 783

Table 168: Bayer's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 786

Table 169: Benitec's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 793

Table 170: Berkeley Lab's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 797

Table 171: BioAxone's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 800

Table 172: Biotecnol's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 803

Table 173: Biotica Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 807

Table 174: Boehringer Ingelheim's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 811

Table 175: Bristol-Myers Squibb's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 819

Table 176: BTG's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 836

Table 177: Calistoga Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 839

Table 178: Callisto Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 842

Table 179: Cambrex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 845

Table 180: CanBas' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 848

Table 181: Cancer Research Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 851

Table 182: Catalyst Biosciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 856

Table 183: Celgene's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 860

Table 184: Cell Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 863

Table 185: Cephalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 866

Table 186: Chroma Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 873

Table 187: CompleGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 877

Table 188: Compugen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 882

Table 189: CoNCERT Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 886

Table 190: Curis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 890

Table 191: Cyclacel's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 894

Table 192: Cylene Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 899

Table 193: Cytokine PharmaSciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 902

Table 194: Cytopia's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 906

Table 195: Dainippon Sumitomo Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 910

Table 196: Deciphera Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 913

Table 197: DeveloGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 922

Table 198: Dyax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 926

Table 199: Eisai's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 929

Table 200: Elara Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 936

Table 201: Eli Lilly's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 939

Table 202: Enkam Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 947

Table 203: EntreMed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 951

Table 204: Exelixis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out 954

Table 205: Galapagos' Included Protein Kinase Drugs in Oncology and Comp

To order this report:

Biotechnology Industry: Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Biotechnology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker